Tumor types	56 expression CD

Negative	Positive

Pleomorphic adenoma	6 cases(40%)	9cases(60%)

Low-grade malignant tumors(Mucoepidermoid carcinoma grade I)	8 cases(100%)	0 case(0%)

high-grade malignant tumors	Mucoepidermoid carcinoma grade III	6 cases(27.3%)	1 case(4.5%)

Adenoid cystic carcinoma	3 cases(13.6%)	12 cases(54.5%)

Tumor types	56 expression CD

Negative	Positive

Pleomorphic adenoma	6 cases(40%)	9cases(60%)

Low-grade malignant tumors(Mucoepidermoid carcinoma grade I)	8 cases(100%)	0 case(0%)

high-grade malignant tum	Mucoepidermoid carcinoma grade III	6 cases(27.3%)	1 case(4.5%)

Adenoid	3 	12

Tumor types	56 expression CD

Negative	Positive

ors	 cystic carcinoma	cases(13.6%)	 cases(54.5%)


	Excluded from Analysis	Included in Analysis

Basic Stats	N = 1534	N = 946	ANOVA

<underline>Age at NAF visit:</underline>

Mean	43.9 *	42.6

Median	42	41

Std Err	0.39	0.42

Min-max	16–89	16–87

			p = 0.04

<underline>Age at breast cancer diagnosis:</underline>

N	81 **	93

Mean	62.0	60.8

Median	62	62

Std Err	1.5	1.27

Min-max	30–89	34–86

			p = 0.54

<underline>Breast cancer:</underline>	<underline>n (%)</underline>	<underline>n (%)</underline>

	90 (6%)	93 (10%)	Chi Square

			p <0.001

<underline>NAF Cytology:</underline>	<underline>n (%)</underline>	<underline>n (%)</underline>

No fluid	929 (61%)	714 (75%)

Insufficient specimen	45 (3%)	19 (2%)

Normal	232 (15%)	89 (9%)

Hyperplasia	234 (15%)	97 (10%)

Atypia	81 (5%)	27 (3%)

[Unable to classify]	13 (1%)

			p <0.001

	Excluded from Analysis	Included in Analysis

Basic Stats	N = 1534	N = 946	ANOVA

Age at NAF visit:

Mean	43.9 *	42.6

Median	42	41

Std Err	0.39	0.42

Min-max	16–89	16–87

			p = 0.04

Age at breast cancer diagnosis:

N	81 **	93

Mean	62.0	60.8

Median	62	62

Std Err	1.5	1.27

Min-max	30–89	34–86

			p = 0.54

Breast cancer:	n (%)	n (%)

	90 (6%)	93 (10%)	Chi Square

	Excluded from Analysis	Included in Analysis

Basic Stats	N = 1534	N = 946	ANOVA

			p <0.001

NAF Cytology:	n (%)	n (%)

No fluid	929 (61%)	714 (75%)

Insufficient specimen	45 (3%)	19 (2%)

Normal	232 (15%)	89 (9%)

Hyperplasia	234 (15%)	97 (10%)

Atypia	81 (5%)	27 (3%)

[Unable to classify]	13 (1%)

			p <0.001


	Total	EDSS mild	EDSS moderate	EDSS severe

Depressive symptoms	No depressive symptoms	Depressive symptoms	No depressive symptoms	Depressive symptoms	No depressive symptoms

n = 173	n = 39a	n = 72	n = 16b	n = 14	n = 16c	n = 16

Disease severity, n (%)

EDSS mild 1.0-3.5	111 (64)	1.8 (1.0-3.5)	1.8 (1.0-3.5)

EDSS moderate 4.0-5.5	30 (17)			4.7 (4.0-5.5)	4.6 (4.0-5.5)

EDSS severe 6.0-9.5	32 (18)					7.3 (6.0-8.0)	7.0 (6.0-8.0)

Disease course, n (%)

Relapsing remitting	106 (61)	35 (90)	62 (86)	3 (19)	4 (29)	0	2 (13)

Secondary progressive	58 (34)	1 (2)	7 (10)	12 (75)	9 (64)	16 (100)	13 (81)

Primary progressive	9 (5)	3 (8)	3 (4)	1 (6)	1 (7)	0	1 (6)


Chinese name	Full scientific name	Parts of plant use	%	Dose of dry plant	Constituent	Dose after extraction	Function in Chinese medicine

Huang Qi 	Radix Astragali 	Dry root 	 	15	Astragaloside 	3.75	Tonifies Qi

Sheng Di 	Rehmannia glutinosa Libosch	Dry root	 	15	 	3.75	Nourishes Yin

Shan Zhu Yu 	Fructus Cornus 	Dry fruit	 	5	Loganin	1.25	Tonifies the liver and kidney and retains the essence

Bai Shao 	Paeonia lactiflora 	Dry root 	 	15	Paeoniflorin	3.75	Nourishes blood and preserves Yin

Dan Pi 	Cortex Moutan Radicis	Dry root and stem 	 	15	Paeonol	3.75	Clears deficient fire and heat

She She Cao 	Herba Hedyotidis Diffusae	Dry leaf	 	15	Oleanic acid	3.75	Clears heat and resolves toxins

Total	 	 	100	80	 	20

Chinese name	Full scientific name	Parts of plant use	%	Dose of dry plant	Constituent	Dose after extraction	Function in Chinese medicine

Dan Pi	Cortex Moutan Radicis	Dry root and stem		15	Paeonol	3.75	Clears deficient fire and heat

She She Cao	Herba Hedyotidis Diffusae	Dry leaf		15	Oleanic acid	3.75	Clears heat and resolves toxins

Total			100	80		20


Genes	5’ Primer sequence	3’ Primer sequence

CD14	CCGCTGCCTCTGGAAG	GGCGAGTGTGCTTGGG

TLR4	GTCCTCAGTGTGCTTGTAG	ATCCTGGCTTGAGTAGATAAC

MD-2	CACCATGAATCTTCCAAAGC	CTTGAAGGAGAATGATATTGTTG

MyD88	CGGATGGTGGTGGTTGTCTC	CGCTTCTGATGGGCACCT

GAPDH	CTGAGTACGTCGTGGAGTC	AAATGAGCCCCAGCCTTC

Genes	5’ Primer sequence	3’ Primer sequence

CD14	CCGCTGCCTCTGGAAG	GGCGAGTGTGCTTGGG

TLR4	GTCCTCAGTGTGCTTGTAG	ATCCTGGCTTGAGTAGATAAC

MD-2	CACCATGAATCTTCCAAAGC	CTTGAAGGAGAATGATATTGTTG

MyD88	CGGATGGTGGTGGTTGT	CG

Genes	5’ Primer sequence	3’ Primer sequence

	CTC	CTTCTGATGGGCACCT

GAPDH	CTGAGTACGTCGTGGAGTC	AAATGAGCCCCAGCCTTC


		Total Number of Samples	Number of Samples < Background PM2.5 Level N (%)	Area (m2) Med (IQR)	Number of Smokers Occupied Med (IQR)	Number of Ventilator Med (IQR)

Pre-ban 	O		23	20	4 (1–9)	10 (4–16


Maternal PCB concentration (ng/g lipid)	Model R2

Model 1: preconception PCBs	0.22

 Explained variation	22%

Model 2: preconception PCBs + prenatal PCBs	0.26

 Explained variation	25%	6%

Model 3: preconception PCBs + prenatal PCBs + postnatal PCBs	0.28

 Explained variation	20%	8%	2%

Model 4: preconception PCBs + prenatal PCBs + postnatal PCBs + breast-feeding duration	0.56

Explained variation	15%	2%	< 1%	32%


	Variables	Expected difference, mean	Expected standard deviation	α	Power %

Primary outcome	10 years risk of CVD (%)	2.5	5.9	0.0166	0.90

Secondary outcomes	WC (cm)	5	14	0.0166	0.75

	BP (mm Hg)	5	12	0.0166	0.88

	RHR (per minutes)	10	20	0.0166	0.97

	HDL (mmol/l)	0.2	0.4	0.0166	0.97

	Non-HDL (mmol/l)	0.45	1.1	0.0166	0.87

	HbA1c (mmol/mol)	0.5	1.1	0.0166	0.94

	FEV1 (L)	-0.36	0.92	00166	0.84

	VO2max	3.5	9	0.0166	0.73

	Sedentary (minutes/day)	60	140	0.0166	0.90

	MVPA (Minutes/day)	20	40	0.0166	0.97


	GmPOPB-S577A_25mer	GmPOPB-D661A_25mer	GmPOPB-S577A_35mer	GmPOPB-H698A_35mer	apo_GmPOPB

Solvent	27	31	43	37	38


Point of view	OQRA	PQRA

Computation	 Every time a request initiated.	Precomputes paths from a source to all destinations.

Scalability	Limited.	 Large-scale networks.

Suitability	When requests arise infrequently.	 When requests arise very frequent.

Pros	Optimal routing during congestion state.	(i) Saves time.(ii) Better scalability.(iii) Improved load balancing.

Cons	Puts excessive time on packet processing.	(i) Path oscillation.(ii) Nonoptimal routing during congestion.(iii) Resources consumption.(iv) Complexity.

Point of view	OQRA	PQRA

Cons	Puts excessive time on packet processing.	(i) Path oscillation.(ii) Nonoptimal routing during congestion.(iii) Resources consumption.(iv) Complexity.


Variable	Total population, N=565	Current use of LARC, N=179

 	n (%)	n (%)

Knowledge of LARC

a) Knowledge of duration of protection from pregnancy

IUD	387 (68.5)	136 (75.98)

Implant	395 (69.9)	139 (77.65)

Injectable	494 (87.4)	161 (89.94)

b) Knowledge of site of administration

IUD	429 (75.9)	148 (82.68)

Implant	453 (80.2)	158 (88.27)

Injectable	519 (91.9)	171 (95.53)

Variable	Total population, N=565

	n (%)

Knowledge of LARC

a) Knowledge of duration of protection from pregnancy

IUD	387 (68.5)

Implant	395 (69.9)

Injectable	494 (87.4)

b) Knowledge of site of administration

IUD	429 (75.9)

Implant	453 (80.2)

Injectable	519 (91.9)

Current use of LARC, N=179

n (%)

a) Knowledge of duration of protection from pregnancy

136 (75.98)

139 (77.65)

161 (89.94)

b) Knowledge of site of administration

148 (82.68)

158 (88.27)

171 (95.53)


Pathway/substance	n	%	P-value

Animal faeces	73	48.7

Raw meat	57	38.0

Soil	40	26.7*	P = 0.036a

Food	39	26.0

Arthropods	37	24.7

No idea	37	24.7

Mother to child	31	20.7

Plants	20	13.3

Environmental contamination	18	12

Claw scratch	1	0.7*	P < 0.0001b

Pathway/substance	n	%	P-value

Animal faeces	73	48.7

Raw meat	57	38.0

Soil	40	26.7*	P = 0.036a

Food	39	26.0

	3	24.

Pathway/substance	n	%	P-value

Arthropods	7	7

No idea	37	24.7

Mother to child	31	20.7

Plants	20	13.3

Environmental contamination	18	12

Claw scratch	1	0.7*	P < 0.0001b


Characteristic	Percentage*	Sample size

Gender (female)	87.8%	983

Age	 	983

 <50 years	2.0%

 50–59 years	14.5%

 60–69 years	30.0%

 70–79 years	33.7%

 ≥80 years	19.7%

BMD based on most recent lowest T-score, mean (SD) 	−2.16 (1.55)	946

Additional fracture risk factors	 	977

 Previous fragility fracture	27.8%

 Systemic glucocorticoids for >3 months	8.5%

 Previous fragility fracture and systemic glucocorticoids for >3 months	3.3%

Length of treatment for osteoporosis	 	980

 <1 year	11.3%

 1–5 years	43.8%

 >5 years	44.9%

Osteoporosis therapy	 	983

 Bisphosphonate	79.0%

 Selective estrogen-receptor modulator	3.0%

 Hormone therapy	2.3%

 Parathyroid hormone	2.2%

 Calcitonin	1.3%

Prescribed supplementation	 	983

 Calcium	84.8%

 Vitamin D	84.8%

Characteristic	Percentage*	Sample size

60–69 years	30.0%

70–79 years	33.7%

≥80 years	19.7%

BMD based on most recent lowest T-score, mean (SD)	−2.16 (1.55)	946

Additional fracture risk factors		977

Previous fragility fracture	27.8%

Systemic glucocorticoids for >3 months	8.5%

Previous fragility fracture and systemic glucocorticoids for >3 months	3.3%

Length of treatment for osteoporosis		980

<1 year	11.3%

1–5 years	43.8%

>5 years	44.9%

Osteoporosis therapy		983

Bisphosphonate	79.0%

Selective estrogen-receptor modulator	3.0%

Hormone therapy	2.3%

Parathyroid hormone	2.2%

Calcitonin	1.3%

Prescribed supplementation		983

Calcium	84.8%

Vitamin D	84.8%


A: Comparison between patients with active TB and control subjects

		P < 0.02	0.02≤P < 0.05	0.05≤P < 0.10

Patients versus control subjects		18	12	24

B: Comparison between stimulated and unstimulated conditions

		P < 0.02	0.02≤P < 0.05	0.05≤P < 0.10

Patients	Mtb antigens versus no stimuli	0	2	2

	Mitogen versus no stimuli	3	5	11

Control subjects	Mtb antigens versus no stimuli	0	1	13

	Mitogen versus no stimuli	2	83	8

A: Comparison between patients with active TB and control subjects

Patients versus control subjects

B: Comparison between stimulated and unstimulated conditions

Patients

Control subjects

A: Comparison between patients with active TB and control subjects

	P < 0.02	0.02≤P < 0.05	0.05≤P < 0.10

	18	12	24

B: Comparison between stimulated and unstimulated conditions

	P < 0.02	0.02≤P < 0.05	0.05≤P < 0.10

Mtb antigens versus no stimuli	0	2	2

Mitogen versus no stimuli	3	5	11

Mtb antigens versus no stimuli	0	1	13

Mitogen versus no stimuli	2	83	8


Study/year	Sample size (I/C)	Setting	Prophylaxis drugs	Comparator	Patient characteristics (I/C)

Age, mean, (years)	Disease severity, median (IQR) or mean (SD)	Patient receiving EN, n/N (%)	MV (%)	Follow up (months)

Alhazzani et al. 2017 [18]	49/42	Mixed	Pantoprazole 40 mg once daily IV	Placebo	62/55	APACHE II score21 (17–26)/22(14–27)	81/91 (89)	100/100	Unknown

El-Kersh et al. 2017 [29]	55/47	MICU	Pantoprazole 40 mg once daily IV	Placebo	62/58	SAPS II score41 (34.5–53)/44 (34–54)	102/102 (100)	100/100	Unknown

Selvanderan et al. 2016 [27]	106/108	Mixed	Pantoprazole 40 mg once daily IV	Placebo	52/52	APACHE III score66 (26)/66 (28)	214/214 (100)	100/100	12

Lin et al. 2016 [28]	60/60	Mixed	Lansoprazole OD 30 mg once daily	No prophylaxis	67/65	APACHE II score21.3 (6.7)/19.9 (6.9)	120/120 (100)	100/100	1

Ben-menachem et al. 1994 [22]	200/100	MICU	Cimetidine 900 mg InfusionSucralfate OD 1 g every 6 h	No prophylaxis	60/60	APACHE II score17.4 (7.3)/16.5 (6.9)	198/300 (67)	74/65	10

Apte et al. 1992 [21]	16/18	MICU	Ranitidine 50 mg/every 6 h IV	No prophylaxis	27/26	MTS score11 (4–16)/10 (6–16)	34/34 (100)	31/22	Unknown

Van den Berg et al. 1985 [23]	14/14	Mixed	Cimetidine 20 mg/kg/every 24 h IV	Placebo	44/48	-	17/28 (61)	100/100	Unknown

Study/year	Sample size (I/C)	Setting	Prophylaxis drugs	Comparator	Patient characteristics (I/C)

Age, mean, (years)	Disease severity, median (IQR) or mean (SD)

Alhazzani et al. 2017 [18]	49/42	Mixed	Pantoprazole 40 mg once daily IV	Placebo	62/55	APACHE II score21 (17–26)/22(14–27)

El-Kersh et al. 2017 [29]	55/47	MICU	Pantoprazole 40 mg once daily IV	Placebo	62/58	SAPS II score41 (34.5–53)/44 (34–54)

Selvanderan et al. 2016 [27]	106/108	Mixed	Pantoprazole 40 mg once daily IV	Placebo	52/52	APACHE III score66 (26)/66 (28)

Lin et al. 2016 [28]	60/60	Mixed	Lansoprazole OD 30 mg once daily	No prophylaxis	67/65	APACHE II score21.3 (6.7)/19.9 (6.9)

Ben-menachem et al. 1994 [22]	200/100	MICU	Cimetidine 900 mg InfusionSucralfate OD 1 g every 6 h	No prophylaxis	60/60	APACHE II score17.4 (7.3)/16.5 (6.9)

Apte et al. 1992 [21]	16/18	MICU	Ranitidine 50 mg/every 6 h IV	No prophylaxis	27/26	MTS score11 (4–16)/10 (6–16)

Van den Berg et al. 1985 [23]	14/14	Mixed	Cimetidine 20 mg/kg/every 24 h IV	Placebo	44/48	-


Experiment	Power (W)	Duration (s)	Tip-to-Tip Distance (mm)	Orientation	Peak Pressure (kPa)

1	5	74	0.5	Parallel	71.6

2	3	105	1.2	Parallel	48.4

3	4	60	2.5	Parallel	5.8

4	5	52	5	Perpendicular	1.9

Experiment	Power (W)	Duration (s)	Tip-to-Tip Distance (mm)	Orientation	Peak Pressure (kPa)

1	5	74	0.5	Parallel	71.6

2	3	105	1.2	Parallel	48.4

		6	2.	Pa	5.8

3	4	0	5	rallel

4	5	52	5	Perpendicular	1.9


Parameter	DB

HISTogram parameter ( HIST )	0.53

Zero Crossing parameter (ZC)	0.70

Auto Regressive coefficients (AR)	1.01

Integral Absolute Value (IAV)	1.24

Parameter

HISTogram parameter ( HIST )

Zero Crossing parameter (ZC)

Auto Regressive coefficients (AR)

Integral Absolute Value (IAV)


Name	Sequence 5'-3'	Description

H-exon 2-3 reverse	ATTTGTGATACCCCTCGACGAG	Normal human ERCC1 transcript reverse primer

Hskin4RTreverse	TGTACAGAGATCGCCCTGCTCTATGC	Larger Human ERCC1 transcript reverse primer

REV1	CGGTCCTCCAGAACCATAGA	Larger Human ERCC1 transcript reverse primer

Oligo dT anchor	GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV (V=A, C or G)	Anchor primer

PCR anchor	GACCACGCGTATCGATGTCGA	Internal anchor primer

Name	Sequence 5'-3'	Description

Oligo dT anchor	GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV (V=A, C or G)	Anchor primer

PCR anchor	GACCACGCGTATCGATGTCGA	Internal anchor primer


Antibiotics	Disk Potency (μg)	Susceptible	Intermediate	Resistant

Chloramphenicol (C)	30	41(100%)	0	0


	Diamniadio District	Rufisque District

Before	During	% Increase	Before	During	% Increase

Number of contraceptives provided	8,351	11,935	43%	17,551	22,779	30%

Pills	4,540	6,097	34%	9,465	11,867	25%

Injectables	3,568	5,277	48%	7,224	9,373	30%

Implants	187	470	151%	536	1,097	105%

Intrauterine devices (IUDs)	56	91	63%	326	442	36%

Long-acting methods	243	561	131%	862	1,539	79%

Couple-years of protection	2,164	3,932	82%	5,977	9,340	56%

	Diamniadio District

Before	During

Number of contraceptives provided	8,351	11,935

Pills	4,540	6,097

Injectables	3,568	5,277

Implants	187	470

Intrauterine devices (IUDs)	56	91

Long-acting methods	243	561

Couple-years of protection	2,164	3,932


	Men with varicocele	Men without varicocele

	Normal sperm	Sperm disturbances	Normal sperm	Sperm disturbances

Dark-eyed men 	25.6%	74.4%	16.7%	83.3%

Light-eyed men	44.4%	55.6%	23.4%	76.6%

P	0.419	0.586

	Men with varicocele	Men without varicocele

	Normal sperm	Sperm disturbances	Normal sperm	Sperm disturbances

P	0.419	0.586


Variables	No (%)

Perceived need*

 Food	114 (97.4%)

 Shelter	88 (75.2%)

 Water (Drinking & Washing)	74 (63.2%)

 Clothes	55 (47.0%)

 Information about Family Members/relatives	35 (29.9%)

 Adsorbents for Menstrual Hygiene	22 (18.8%)

 Mobiles	17 (14.5%)

 Medicine/First aid	13 (11.1%)

 Safe place	12 (10.3%)

 Soap	8 (6.8%)

 Cattle	7 (6.0%)

Variables	No (%)

Clothes	55 (47.0%)

Information about Family Members/relatives	35 (29.9%)

Adsorbents for Menstrual Hygiene	22 (18.8%)

Mobiles	17 (14.5%)

Medicine/First aid	13 (11.1%)

Safe place	12 (10.3%)

Soap	8 (6.8%)

Cattle	7 (6.0%)


	X. dendrorhousstrains

	CBS 6938	CBS-CYP51+/−

Cultivation Time (h)	48	120	48	120


Taxon	Dry (n = 16)	Wet (n = 16)	Pooled SEM	P-value	q-value

Actinobacteria	16.5	0.1	3.8	0.011	0.068

Bacteroidetes	8.7	15.9	4.7	0.010	0.062


Past Week NSSI Measures	n	d	p

Number of NSSI episodes (ABASI)	1514	.13	.01

Medical severity of NSSI (ABASI)	1239	.29	<.001

Impulsivity of NSSI (ABASI)	1234	-.01	.87

Craving for NSSI (ABUSI total score)	1476	1.16	<.001

Past Year NSSI Methods (ABASI)

Cut	676	.13	.09

Scratch	676	.20	.01

Burn	676	.12	.11

Tattoo/Pierce	676	.01	.91

Choke	676	.33	<.001

Pull Hair	676	.20	.01

Draw Blood	676	.09	.25

Insert/Embed	676	.19	.01

Hit	345	.45	<.001

Bang	676	.28	<.001

Prevent Wound Healing	676	.24	.002

Fall Down	676	.00	.99

Break Bones	676	.11	.16

Gouge	676	.05	.51

Fight	676	.11	.14

Ingest/Swallow	676	.09	.25

Mutilate Genitals	343	.00	1

Worsen Medical Condition/Ignore Medical Advice	676	.23	.003

Past Year Number of NSSI Methods (ABASI)	676	.52	<.001

Past Year Number of Days with NSSI (ABASI)	345	.65	<.001


Multivariate Analysis

p Value

0.020

0.010


Gene ID	Gene	Protein description	Mean RPKM WT	Mean RPKM ΔgacA	ΔgacA/WT	P-value

gacS/gacA

 Pchl3084_3491	gacA	Response regulator	266.9	1.43	0.01	0.00

 Pchl3084_4333	gacS	Sensor protein	29.17	21.15	0.73	0.05

phz genes

 Pchl3084_4951	phzX	Phenazine biosynthesis protein	40.50	4.52	0.11	0.03

 Pchl3084_4952	phzY	Phenazine biosynthesis protein	37.87	5.28	0.14	0.03

 Pchl3084_4953	phzF	Phenazine biosynthesis protein	20.00	2.63	0.13	0.03

 Pchl3084_4954	phzA	Phenazine biosynthesis protein	8.52	0.78	0.09	0.15

 Pchl3084_4955	phzB	Phenazine biosynthesis protein	13.47	2.08	0.15	0.04

 Pchl3084_4956	phzC	Phenazine biosynthesis protein	8.24	1.90	0.23	0.00

 Pchl3084_4957	phzD	Phenazine biosynthesis protein	7.63	1.40	0.18	0.10

 Pchl3084_4958	phzO	Phenazine biosynthesis protein	44.23	21.70	0.49	0.06

Regulatory genes

 Pchl3084_4949	phzI	Autoinducer synthase	5.24	1.50	0.29	0.01

 Pchl3084_4950	phzR	Transcriptional activator	125.1	67.12	0.54	0.02

 Pchl3084_1189	rpoS	Sigma factor	1045.7	101.8	0.10	0.03

 Pchl3084_5155	pip	Phenazine-inducing protein	123.4	105.4	0.85	0.04

 Pchl3084_1659	iopA	Inducer of phenazine A	49.10	8.35	0.17	0.01

 Pchl3084_1660	iopB	Inducer of phenazine B	20.71	2.51	0.12	0.00

 Pchl3084_3224	rpeA	Sensor histidine kinase	46.78	49.28	1.05	0.67

 Pchl3084_3225	rpeB	Response regulator	45.37	55.20	1.22	0.07

 Pchl3084_2449	csaI	Autoinducer synthase	8.15	8.72	1.07	0.65

 Pchl3084_2451	csaR	Transcriptional activator	0.54	0.38	0.71	0.50

 Pchl3084_0554	hfq	RNA chaperone	1642.19	1408.2	0.84	0.28

 Pchl3084_4387	rsmA	Translational regulator	151.82	307.24	2.02	0.03

 Pchl3084_2024	rsmE	Translational regulator	292.7	204.83	0.70	0.06

 Pchl3084_3970	rsmX	ncRNA	1486.51	201.13	0.14	0.02

 Pchl3084_5419	rsmY	ncRNA	38112.4	329.2	0.01	0.02

 Pchl3084_1190	rsmZ	ncRNA	1679.64	261.26	0.16	0.05


Grade	Description

0	No changes

1	Doubtful narrowing of joint space and possible osteophytic lipping

2	Definite osteophytes and possible narrowing of joint space

3	Moderate multiple osteophytes, definite narrowing of joint space, and some sclerosis, and possible deformity of bone ends

4	Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends

Description

No changes

Doubtful narrowing of joint space and possible osteophytic lipping

Definite osteophytes and possible narrowing of joint space

Moderate multiple osteophytes, definite narrowing of joint space, and some sclerosis, and possible deformity of bone ends

Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends


	cELISA assay	Total

P	N

Skin test	P	45	31	76

N	45	177	222

Total	90	208	298


Indicator	Baseline	Mid-term	End-term	DID adjusted BL-ML	Sig.	DID adjusted BL-EL	Sig.

Comparison	Intervention	Comparison	Intervention	Comparison	Intervention

%	N	%	N	%	N	%	N	%	N	%	N

Proportion of women reporting health worker introduction	26%	53	37%	68	30%	89	38%	120	40%	62	49%	85	−4%	0.77	−4%	0.82

Proportion of women reporting having been clinically examined	57%	53	46%	68	99%	89	96%	120	92%	62	91%	85	5%	0.73	6%	0.75

Proportion of women reporting having received an explanation of the examination	100%	30	100%	31	64%	88	58%	115	54%	57	58%	77	−5%	0.69	−2%	0.85

Proportion of women reporting having received medication/treatment	92%	53	71%	68	87%	89	88%	120	66%	62	79%	85	23%	0.07	29%	0.03*

Proportion of women reporting having received an explanation for the medication	59%	49	63%	48	42%	77	46%	106	56%	41	73%	67	−3%	0.85	12%	0.54

Proportion of women reporting having had a blood test done	26%	53	47%	68	21%	89	8%	120	23%	62	36%	85	−35%	0.03	−2%	0.90

Proportion of women reporting having received an explanation for the test	93%	14	75%	32	32%	19	30%	10	64%	14	65%	31	9%	0.69	10%	0.65

Proportion of women reporting consent being sought before procedures were performed	55%	53	61%	66	62%	87	63%	112	68%	60	75%	77	−5%	0.73	1%	0.96

Proportion of women having been encouraged to ask questions	36%	53	49%	68	25%	89	33%	120	45%	62	58%	85	−8%	0.63	2%	0.89

Proportion of women reporting being offered to have guardian during delivery	42%	53	57%	68	22%	89	58%	120	50%	62	55%	85	18%	0.29	3%	0.87

Proportion of women reporting their privacy/confidentiality being protected	96%	53	96%	68	91%	89	94%	120	90%	62	96%	85	3%	0.67	8%	0.55

Proportion of women reporting blood pressure was checked before delivery	53%	53	51%	68	49%	89	37%	120	61%	62	65%	85	−15%	0.22	19%	0.26

Proportion of women reporting blood pressure was checked after delivery	40%	53	44%	68	66%	89	57%	116	45%	58	68%	81	−13%	0.36	19%	0.25

Indicator	Baseline	Mid-term	End-term	DID adjusted BL-ML	Sig.	DID adjusted BL-EL	Sig.

Comparison	Intervention	Comparison	Intervention	Comparison	Intervention

%	N	%	N	%	N	%	N	%	N	%	N

Proportion of women reporting being offered to have guardian during delivery	42%	53	57%	68	22%	89	58%	120	50%	62	55%	85	18%	0.29	3%	0.87

Proportion of women reporting their privacy/confidentiality being protected	96%	53	96%	68	91%	89	94%	120	90%	62	96%	85	3%	0.67	8%	0.55

Proportion of women reporting blood pressure was checked before delivery	53%	53	51%	68	49%	89	37%	120	61%	62	65%	85	−15%	0.22	19%	0.26

Proportion of women reporting blood pressure was checked after delivery	40%	53	44%	68	66%	89	57%	116	45%	58	68%	81	−13%	0.36	19%	0.25


Country	Region	Classification category of country for ZIKV transmission as per WHO	Number of cases reported

American Samoa	American Samoa	Category 3 (interrupted transmission areas)	51

Angola	Angola	Category 1 (virus transmission areas followed by new/re introduction of virus)	2

Argentina	Chaco, Formosa, Salta, Tucuman	Category 1 (virus transmission areas followed by new/re introduction of virus)	4

Bahamas	Bahamas	Category 1 (virus transmission areas followed by new/re introduction of virus)	25

Bangladesh	Bangladesh	Category 2 (virus transmission areas following previous circulation of virus)	1

Brazil	Acre, Alagoas, Amapa Amazonas, Ceara, Distrito Federal, Espirito Santo, Goias, Mato Grosso, Mato Grosso Do Sul, Minas Gerais, Para, Paraiba, Parana, Pernambuco, Piaui, Rio Grande Do Norte, Rio Grande Do Sul, Rondonia, Roraima, Santa Catarina, Sao Paulo, Sergipe, Tocantin	Category 1 (virus transmission areas followed by new/re introduction of virus)	27

	Bahia, Maranhao	Category 2 (newly documented intense transmission areas)

	Rio de Janeiro	Category 2 (virus transmission areas following previous circulation of virus)

Colombia	Colombia	Category 1 (virus transmission areas followed by new/re introduction of virus)	46

Costa Rica	Costa Rica	Category 1 (virus transmission areas followed by new/re introduction of virus)	23

Dominican Republic	Dominican Republic	Category 1 (virus transmission areas followed by new/re introduction of virus)	30

India	Gujarat, Tamil Nadu	Category 2 (virus transmission areas following previous circulation of virus)	2

Indonesia	Bali, Bangka Belitung, Banten, Bengkulu, Daerah Istimewa Yogyakarta, Dki Jakarta, Gorontalo, Jambi, Jawa Barat, Jawa Tengah, Jawa Timur, Kalimantan Barat, Kalimantan Selatan, Kalimantan Tengah, Kalimantan Timur, Kepulauan-Riau, Lampung, Maluku, Maluku Utara, Nanggroe Aceh Darussalam, Nusa Tenggara Barat, Nusa Tenggara Timur, Papua, Papua Barat, Riau, Sulawesi Barat, Sulawesi Selatan, Sulawesi Tengah, Sulawesi Tenggara, Sulawesi Utara, Sumatera Barat, Sumatera Selatan, Sumatera Utara	Category 2 (virus transmission areas following previous circulation of virus)	31

Malaysia	Malaysia	Category 2 (virus transmission areas following previous circulation of virus)	8

Mexico	Aguascalientes, Baja California, Baja California Sur, Campeche, Chiapas, Coahuila, Colima, Guerrero, Hidalgo, Jalisco, Michoacan, Morelos, Nayarit, Nuevo Leon, Oaxaca, Puebla, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, Tabasco, Tamaulipas, Veracruz, Yucatan, Zacatecas	Category 1 (virus transmission areas followed by new/re introduction of virus)	25

Philippines	Philippines	Category 2 (virus transmission areas following previous circulation of virus)	57

Thailand	Thailand	Category 2 (newly documented intense transmission areas)	33

United States of America	Cameron	Category 1 (virus transmission areas followed by new/re introduction of virus)	202

	Broward, Miami-Dade, Palm Beach, Pinellas	Category 3 (interrupted transmission areas)

Vietnam	Vietnam	Category 2 (newly documented intense transmission areas)	232

Country	Region	Classification category of country for ZIKV transmission as per WHO	Number of cases reported

Costa Rica	Costa Rica	Category 1 (virus transmission areas followed by new/re introduction of virus)	23

Dominican Republic	Dominican Republic	Category 1 (virus transmission areas followed by new/re introduction of virus)	30

India	Gujarat, Tamil Nadu	Category 2 (virus transmission areas following previous circulation of virus)	2

Indonesia	Bali, Bangka Belitung, Banten, Bengkulu, Daerah Istimewa Yogyakarta, Dki Jakarta, Gorontalo, Jambi, Jawa Barat, Jawa Tengah, Jawa Timur, Kalimantan Barat, Kalimantan Selatan, Kalimantan Tengah, Kalimantan Timur, Kepulauan-Riau, Lampung, Maluku, Maluku Utara, Nanggroe Aceh Darussalam, Nusa Tenggara Barat, Nusa Tenggara Timur, Papua, Papua Barat, Riau, Sulawesi Barat, Sulawesi Selatan, Sulawesi Tengah, Sulawesi Tenggara, Sulawesi Utara, Sumatera Barat, Sumatera Selatan, Sumatera Utara	Category 2 (virus transmission areas following previous circulation of virus)	31

Malaysia	Malaysia	Category 2 (virus transmission areas following previous circulation of virus)	8

Mexico	Aguascalientes, Baja California, Baja California Sur, Campeche, Chiapas, Coahuila, Colima, Guerrero, Hidalgo, Jalisco, Michoacan, Morelos, Nayarit, Nuevo Leon, Oaxaca, Puebla, Quintana Roo, San Luis Potosi, Sinaloa, Sonora, Tabasco, Tamaulipas, Veracruz, Yucatan, Zacatecas	Category 1 (virus transmission areas followed by new/re introduction of virus)	25

Philippines	Philippines	Category 2 (virus transmission areas following previous circulation of virus)	57

Thailand	Thailand	Category 2 (newly documented intense transmission areas)	33

United States of America	Cameron	Category 1 (virus transmission areas followed by new/re introduction of virus)	202

	Broward, Miami-Dade, Palm Beach, Pinellas	Category 3 (interrupted transmission areas)

Vietnam	Vietnam	Category 2 (newly documented intense transmission areas)	232


Number of criteria positively scored	Sensitivity	Specificity

1. criteria or more	0.88	0.31

2. criteria or more	0.85	0.41

3. criteria or more	0.83	0.52

4. criteria or more	0.78	0.69

5. criteria or more	0.70	0.85

6. criteria or more	0.50	0.94

7. criteria	0.18	0.98


Confounder	Variables	How to measure

Demographic characteristics	Age, sex, social status, family size, educational attainment, occupational history, income	Questionnaire

Lifestyle	Smoking, alcohol	Questionnaire

Genetic factor	Family history of diabetes/hypertension	Questionnaire

Drugs	Different medications for diabetes and hypertension	Clinical record


	Nucleotides	Amino acids

	MCMCTreeWAG + G	PhyloBayesLG + G	PhyloBayesCAT-GTR + G	MCMCTree GTR + G	PhyloBayes GTR + G	PhyloBayesCAT-GTR + G	TimeTreemean/medianb


Variable	Year/Region	With WNV Mean Rank	Without WNV Mean Rank	z-score	P

Precipitation	2002/East	701	695	-0.16	0.88

	2002/West	776	619	-2.31	0.021

	2003/East	733	694	-0.53	0.6

	2003/West	465	637	-4.57	<0.001


Tissue type	Pegcantratinib (MF)	CT340 (MF)	Ratio

Skin with anagen follicles	1.05	1.05	1.00

Cylindroma and spiradenoma	0.97	0.96	1.01

Cylindroma only	1.07	1.05	1.02

Spiradenoma only:	0.92	1.01	0.91

– Mean	1.00	1.02	0.99

– SD	0.07	0.04	0.05

– CV (%)	7.1	3.9	5.0

Tissue type	Pegcantratinib (MF)	CT340 (MF)	Ratio

Cylindroma and spiradenoma	0.97	0.96	1.01

Cylindroma only	1.07	1.05	1.02

Spiradenoma only:	0.92	1.01	0.91

– Mean	1.00	1.02	0.99

– SD	0.07	0.04	0.05

– CV (%)	7.1	3.9	5.0


Case no.	@Age/ $Gender	Stage	Grade	#Recurrence	MSI

BC 1	45/M	T2	High, G3	2	*High (BAT – 26, BAT – 40)

BC 2	59/M	T1	High, G2	1	High (BAT – 26, BAT – 40, D9S1851)

BC 3	66/M	Ta	Low, G1	0	High (D9S283, D9S1851)

BC 4	39/M	T2	High, G3	0	High (BAT – 26, BAT – 40, D9S283)

BC 5	72/M	T2	High, G3	0	High (BAT – 40, D9S1851)

BC 6	59/M	T2	High, G2	1	Low (D9S1851)

BC 7	78/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 8	52/M	Ta	High, G2	0	High (BAT – 40, D9S283, D9S1851)

BC 9	71/M	Ta	High, G2	0	**Low (BAT – 40)

BC 10	84/M	T1	High, G2	0	***MSS

BC 11	55/M	T1	High, G1	0	MSS

BC 12	53/M	T2	High, G2	0	Low (D18S58)

BC 13	52/M	T3	High, G3	0	High (D9S283, D9S1851)

BC 14	40/M	T3	High, G3	0	MSS

BC 15	55/M	T2	High, G3	0	MSS

BC 16	60/M	T2	High, G3	0	High (BAT – 40, D9S283, D18S58)

BC 17	66/M	T1	High, G3	1	High (BAT – 40, D2S123, D9S283, D9S1851, D18S58)

BC 18	80/M	T1	High, G3	1	High (BAT – 26, D9S283, D18S58)

BC 19	42/M	T1	High, G2	0	Low (D9S283)

BC 20	73/M	T3a	High, G3	0	MSS

BC 21	55/M	T2	High, G3	0	Low (D2S123)

BC 22	58/M	T2	High, G3	0	High (BAT – 26, D2S123)

BC 23	70/M	T1	High, G2	0	Low (BAT – 26)

BC 24	53/M	Ta	High, G3	0	High (D9S1851, D18S58)

BC 25	60/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 26	54/M	Ta	Low, G1	0	MSS

BC 27	72/M	Ta	High, G2	0	MSS

BC 28	58/M	T1	High, G3	0	Low (D9S283)

BC 29	80/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 30	64/M	Ta	High, G2	2	Low (BAT – 40)

BC 31	74/M	Ta	High, G3	0	High (D9S283, D9S1851)

BC 32	60/M	T1	Low, G1	0	MSS

BC 33	41/M	T1	Low, G1	3	Low (BAT – 26)

BC 34	66/ F	T2	High, G3	0	High (D2S123, D9S283)

BC 35	53/M	T1	Low, G1	0	Low (D2S123)

BC 36	66/M	T1	High, G2	1	High (D2S123, D9S283, D18S58)

BC 37	55/M	T2	High, G3	0	High (BAT – 26, BAT – 40, D9S1851)

BC 38	65/M	T2	High, G3	0	Low (D18S58)

BC 39	69/M	T1	Low, G1	0	Low (D9S283)

BC 40	74/M	T1	High, G2	1	MSS

BC 41	72/ F	T2	Low, G1	0	MSS

BC 42	71/M	T1	High, G3	1	Low (D9S283)

BC 43	64/M	T2	High, G3	0	High (BAT – 40, D9S1851)

BC 44	73/M	T1	High, G2	1	Low (D9S283)

Case no.	@Age/ $Gender	Stage	Grade	#Recurrence	MSI

BC 1	45/M	T2	High, G3	2	*High (BAT – 26, BAT – 40)

BC 2	59/M	T1	High, G2	1	High (BAT – 26, BAT – 40, D9S1851)

BC 3	66/M	Ta	Low, G1	0	High (D9S283, D9S1851)

BC 4	39/M	T2	High, G3	0	High (BAT – 26, BAT – 40, D9S283)

BC 5	72/M	T2	High, G3	0	High (BAT – 40, D9S1851)

BC 6	59/M	T2	High, G2	1	Low (D9S1851)

BC 7	78/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 8	52/M	Ta	High, G2	0	High (BAT – 40, D9S283, D9S1851)

BC 9	71/M	Ta	High, G2	0	**Low (BAT – 40)

BC 10	84/M	T1	High, G2	0	***MSS

BC 11	55/M	T1	High, G1	0	MSS

BC 12	53/M	T2	High, G2	0	Low (D18S58)

BC 13	52/M	T3	High, G3	0	High (D9S283, D9S1851)

BC 14	40/M	T3	High, G3	0	MSS

BC 15	55/M	T2	High, G3	0	MSS

BC 16	60/M	T2	High, G3	0	High (BAT – 40, D9S283, D18S58)

BC 17	66/M	T1	High, G3	1	High (BAT – 40, D2S123, D9S283, D9S1851, D18S58)

BC 18	80/M	T1	High, G3	1	High (BAT – 26, D9S283, D18S58)

BC 19	42/M	T1	High, G2	0	Low (D9S283)

BC 20	73/M	T3a	High, G3	0	MSS

BC 21	55/M	T2	High, G3	0	Low (D2S123)

BC 22	58/M	T2	High, G3	0	High (BAT – 26, D2S123)

BC 23	70/M	T1	High, G2	0	Low (BAT – 26)

BC 24	53/M	Ta	High, G3	0	High (D9S1851, D18S58)

BC 25	60/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 26	54/M	Ta	Low, G1	0	MSS

BC 2			High,		MS

Case no.	@Age/ $Gender	Stage	Grade	#Recurrence	MSI

7	72/M	Ta	 G2	0	S

BC 28	58/M	T1	High, G3	0	Low (D9S283)

BC 29	80/M	T2	High, G3	0	High (D9S283, D9S1851)

BC 30	64/M	Ta	High, G2	2	Low (BAT – 40)

BC 31	74/M	Ta	High, G3	0	High (D9S283, D9S1851)

BC 32	60/M	T1	Low, G1	0	MSS

BC 33	41/M	T1	Low, G1	3	Low (BAT – 26)

BC 34	66/ F	T2	High, G3	0	High (D2S123, D9S283)

BC 35	53/M	T1	Low, G1	0	Low (D2S123)

BC 36	66/M	T1	High, G2	1	High (D2S123, D9S283, D18S58)

BC 37	55/M	T2	High, G3	0	High (BAT – 26, BAT – 40, D9S1851)

BC 38	65/M	T2	High, G3	0	Low (D18S58)

BC 39	69/M	T1	Low, G1	0	Low (D9S283)

BC 40	74/M	T1	High, G2	1	MSS

BC 41	72/ F	T2	Low, G1	0	MSS

BC 42	71/M	T1	High, G3	1	Low (D9S283)

BC 43	64/M	T2	High, G3	0	High (BAT – 40, D9S1851)

BC 44	73/M	T1	High, G2	1	Low (D9S283)


Statements	At my PHCC,a management is positive toward our work with promotion of healthy lifestyles	At my PHCC, we collaborate with other stakeholders such as municipalities and community associations about our patients’ lifestyles	At my PHCC, there are incentives to promote healthy lifestyles among our patients	At my PHCC, there are local guidelines/care programs on how we should promote healthy lifestyles among our patients	At my PHCC, there are many factors that facilitate the promotion of healthy lifestyles among our patients	At my PHCC, there are many factors that hinder the promotion of healthy lifestyles among our patients	I perceive there is a need for National CPGsb for lifestyle interventions in the work at my PHCC

Characteristics	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value

Profession		0.782		0.207		0.465		0.618		0.154		0.729		0.049

Registered nurse	80		37		60		63		37		17		77

Public health nurse	71		22		57		51		42		17		84

Physician	68		20		63		50		43		12		65

Residentc	68		14		50		50		14		18		68

General practitioner	72		19		72		72		38		25		75

Years in profession		0.489		0.829		0.111		0.948		0.075		0.861		0.783

0–10	74		22		54		51		27		18		79

≥11	70		23		63		52		37		17		78

Total	71		22		59		51		33		17		78

Statements	At my PHCC,a management is positive toward our work with promotion of healthy lifestyles	At my PHCC, we collaborate with other stakeholders such as municipalities and community associations about our patients’ lifestyles	At my PHCC, there are incentives to promote healthy lifestyles among our patients	At my PHCC, there are local guidelines/care programs on how we should promote healthy lifestyles among our patients	At my PHCC, there are many factors that facilitate the promotion of healthy lifestyles among our patients	At my PHCC, there are many factors that hinder the promotion of healthy lifestyles among our patients	I perceive there is a need for National CPGsb for lifestyle interventions in the work at my PHCC

Characteristics	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value	%	P-value

Profession		0.782		0.207		0.465		0.618		0.154		0.729		0.049

Registered nurse	80		37		60		63		37		17		77

Public health nurse	71		22		57		51		42		17		84

Physician	68		20		63		50		43		12		65

Residentc	68		14		50		50		14		18		68

General practitioner	72		19		72		72		38		25		75

Year		0.		0.8		0.		0		0.075		0.861		0

Statements	At my PHCC,a management is positive toward our work with promotion of healthy lifestyles	At my PHCC, we collaborate with other stakeholders such as municipalities and community associations about our patients’ lifestyles	At my PHCC, there are incentives to promote healthy lifestyles among our patients	At my PHCC, there are local guidelines/care programs on how we should promote healthy lifestyles among our patients	At my PHCC, there are many factors that facilitate the promotion of healthy lifestyles among our patients	At my PHCC, there are many factors that hinder the promotion of healthy lifestyles among our patients	I perceive there is a need for National CPGsb for lifestyle interventions in the work at my PHCC

Characteristics	%	P-value	%	P-value	%	P-value	%	P-value	%	%	%	P-value

s in profession		489		29		111		.948				.783

0–10	74		22		54		51		27	18	79

≥11	70		23		63		52		37	17	78

Total	71		22		59		51		33	17	78


Type of triangulation	Example

Data source triangulation	Existing data review	Analyzed main health problem by reviewing existing health data from CDC

	Investigation	Prioritized health problem by investigating health problem and risk factors with different methods

Methods triangulation	Participation (Ranking)	Prioritized health problem by listing and ranking health concerns (people's perceived needs and priorities)

	FGD	Discussed the health problems, risk factors and their influencing factors (people's perceived needs, priorities, influence factors)

	Key informant interview	Assessed the health resources for health promotion (resources, policy)

	Questionnaires	Surveyed the health problems ("actual needs"), risk factors

Researchers triangulation	Teachers	Role of moderator in 4 FGDs and key informants interviews, and analyzed all FGDs and key informants interviews

	Graduates	Role of moderator in 8 FGDs

Type of triangulation

Data source triangulation	Existing data review

	Investigation

Methods triangulation	Participation (Ranking)

	FGD

	Key informant interview

	Questionnaires

Researchers triangulation	Teachers

	Graduates

Example

Analyzed main health problem by reviewing existing health data from CDC

Prioritized health problem by investigating health problem and risk factors with different methods

Prioritized health problem by listing and ranking health concerns (people's perceived needs and priorities)

Discussed the health problems, risk factors and their influencing factors (people's perceived needs, priorities, influence factors)

Assessed the health resources for health promotion (resources, policy)

Surveyed the health problems ("actual needs"), risk factors

Role of moderator in 4 FGDs and key informants interviews, and analyzed all FGDs and key informants interviews

Role of moderator in 8 FGDs


		Menstrual	Follicular	Luteal

		r	95% CI	r	95% CI	r	95% CI

Depressiveness (CES-D)	CO concentration	0.490**	0.03–0.78	0.484**	0.02–0.78	0.607***	0.20–0.84

Menstrual phase-associated symptoms(MDQ)	Number of cigarettes	0.405*	0.05–0.67	0.097	−0.28–0.45	0.530**	0.08–0.80

	CO concentration	0.488**	0.03–0.78	0.274	−0.10–0.58	0.588**	0.17–0.83


Classification results L2-norm SVM

Features	Accuracy (%)	Accuracy p-value	Sensitivity (%)	Specificity (%)	Sparsity (%)	Stability (%)

Event-related fMRI dataset

Sparse inverse covariance	73.68	0.01⁎	73.68	73.68	–	37.81 ± 0.26

Full inverse covariance	44.73	> 0.05	47.37	42.11	–	9.90 ± 0.78

Correlation	68.42	0.02⁎	84.21	52.63	–	9.29 ± 1.56

Partial correlation	65.78	> 0.05	73.68	57.89	–	11.33 ± 0.16

Block-related fMRI dataset

Sparse inverse covariance	78.33	0.01⁎	80.00	76.67	–	25.81 ± 0.45

Full inverse covariance	40.00	> 0.05	20.00	60.00	–	12.81 ± 0.89

Correlation	60.00	> 0.05	86.67	33.33	–	8.61 ± 2.17

Partial correlation	58.33	> 0.05	53.33	63.33	–	10.93 ± 0.78


Sample month	Raw sludge enteric virus (PFU/4 g)	Treated biosolids enteric virus (PFU/4 g)

1	< 1	< 1

2	< 1	< 1

3	< 1	< 1

4	< 1	< 1

5	< 1	< 1

6	5	< 1

7	2	< 1

8	1	< 1

9	1	< 1

10	7	< 1

11	6	1

12	31	< 1


	Landmarks on single curves

Sellion	The most posterior point of the frontonasal soft tissue contour in the midline of the base of the nasal root

The point of maximal curvature of the mid‐line nasal profile curve at its nasal root end

Subnasale	The point where the nasal septum merges with the upper cutaneous lip in the mid‐sagittal plane

The point of maximal curvature on the mid‐line curve at the base of the nasal septum

Alare	The most lateral point on each alar contour

The point of maximal curvature along the alar curve

Alare crest	The facial insertion of each alar base

The point of maximum curvature on the alar curve where this meets the paranasal area

Cheilion	The point located at each labial commissure

The point of maximum curvature at the lateral end of the labial seal curve

Sublabiale	The most posterior mid‐point on the labiomental soft tissue contour that defines the border between the lower lip and the chin

The point of maximal curvature in the mid‐line curve as it passes through the mentolabial sulcus

Tragion	The point located at the upper margin of each tragus

The point of maximum curvature at the superior end of the tragus curve

Otobasion inferius	The point of attachment of the ear lobe to the cheek, which determines the lower border of the ear insertion

The final point at the preauricular end of the ear rim curve.

	Landmarks on single curves

Tragion	The point located at the upper margin of each tragus

The point of maximum curvature at the superior end of the tragus curve

Otobasion inferius	The point of attachment of the ear lobe to the cheek, which determines the lower border of the ear insertion

The final point at the preauricular end of the ear rim curve.


Characteristic	Standardized coefficients	P-value	95 % Confidence Interval for B

Beta	Lower bound	Lower bound

Number of medications for each patient	0.556	<0.001	0.196	0.288

Patient age group	0.045	0.381	−0.090	0.235

Number of comorbid diseases the patient have	0.049	0.367	−0.056	0.151

Characteristic	Standardized coefficients	P-value	95 % Confidence Interval for B

Beta	Lower bound	Lower bound

Number of comorbid diseases the patient have	0.049	0.367	−0.056	0.151


Highest stage of education achieved by participants’ parent(s) No. (%)	Entry route into Undergraduate Medical Education No. (%)	Medical Degree Type No. (%)	Medical Degree Stage No. (%)

- Primary Level 1 (5)- Secondary Level14 (70)- Tertiary Level 5(25)	-Direct entry from Tertiary Education15 (75)-Gap year between Tertiary Education and Medical School 2 (10)-Graduate Entry 3 (15)	-Extended (6 Years) 11 (55)-MBBS (5 Years) 9 (45)	-Pre-Clinical Stage 10 (50%)-Clinical Stage 10 (50%)

Total 20(100)	Total 20(100)	Total 20(100)	Total 20(100)


Antibody (host, clonality, Company)	Purpose	Dilution

FGFR1 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)	IHC	1:150

FGFR2 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)	IHC	1:150

FGF7 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)	IHC	1:150

FGF7 (rabbit, polyclonal, Abcam, Cambridge, UK)	WB	1:200

FGF10 (rabbit, polyclonal, Santa Cruz Biotechnology, CA)	IHC	1:150

FGF10 (goat, polyclonal, Peprotech Inc., Rocky Hill, NJ)	WB	1:200

p-p44/42 MAPK (Thr202/Tyr204) (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

Akt (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

p-Akt (Ser473) (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

Actin (mouse, monoclonal, Amersham, Buckinghamshire, UK)

Antibody (host, clonality, Company)	Purpose	Dilution

FGF10 (goat, polyclonal, Peprotech Inc., Rocky Hill, NJ)	WB	1:200

p-p44/42 MAPK (Thr202/Tyr204) (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

Akt (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

p-Akt (Ser473) (rabbit, polyclonal, Cell Signaling, Beverly, MA)	WB	1:1,000

Actin (mouse, monoclonal, Amersham, Buckinghamshire, UK)


Characteristics	Controls n = 67	NSTEMI n = 38	STEMI n = 30

Age	66 ± 12	72 ± 15	72 ± 13

M/F	46/21	29/9	21/9

Diabetes Mellitus	8	8	4

Prior IHD	29	18	12

Hemoglobine, g/l	135 ± 15	132 ± 15	132 ± 16

Platelet count, ×109/l	224 ± 74	218 ± 51	222 ± 66

Cholesterol mmol/l	-	4,67 ± 0,94	4,60 ± 0,79

Triglycerides mmol/l	-	1,19 ± 0,46	1,28 ± 0,94

BMI	-	24 ± 2,8	27 ± 3,2

Characteristics	Controls n = 67

Age	66 ± 12

M/F	46/21

Diabetes Mellitus	8

Prior IHD	29

Hemoglobine, g/l	135 ± 15

Platelet count, ×109/l	224 ± 74

Cholesterol mmol/l	-

Triglycerides mmol/l	-

BMI	-


Raw material	Cellulose	Hemicellulose	Lignin	Ash

Wheat straw	44.2 (1.8)	26.5 (1.9)	22.4 (1.7)	2.8 (0.6)


	Up/Down-regulatedc	Regulated by

	Genea	Enzymeb	CAZy family	ΔxlnR	ΔaraR	ΔrhaR	ΔgalX	ΔamyR	This study	Literature	Reference

E-1	An15g04900 (eglD)	LPMO	AA9	2.1	−1.2	−1.7	−1.6	−1.8	nd	nr	[38]

An03g00190 (pelB)	PEL	PL1	–	–	–	1.2	1.0	nd	nr	[73]

E-2	An07g09760	BGL	GH3	–	–	–	–	–	nd	nr	[38]

An08g01100	EXG	GH5	1.6	1.1	1.1	–	3.8	nd	nr	[38]

An11g03200 (inuA/inuB)	INU	GH32	–	–	–	–	–	nd	InuR	[8, 79]

An12g08280 (inuE/inu1)	INX	GH32	2.9	2.0	1.9	5.2	4.1	nd	InuR	[8]

An02g04900 (pgaB)	PGA	GH28	2.6	−2.3	–	2.2	−2.1	nd	GaaR	[15, 34, 80]

An08g11070 (sucA/suc1)	SUC	GH32	–	–	–	–	–	nd	InuR	[9, 81, 82]

	Genea	Enzymeb

E-1	An15g04900 (eglD)	LPMO

An03g00190 (pelB)	PEL

E-2	An07g09760	BGL

An08g01100	EXG

An11g03200 (inuA/inuB)	INU

An12g08280 (inuE/inu1)	INX

An02g04900 (pgaB)	PGA

An08g11070 (sucA/suc1)	SUC

	Up/Down-regulatedc	Regulated by

CAZy family	ΔxlnR	ΔaraR	ΔrhaR	ΔgalX	ΔamyR	This study	Literature	Reference

AA9	2.1	−1.2	−1.7	−1.6	−1.8	nd	nr	[38]

PL1	–	–	–	1.2	1.0	nd	nr	[73]

GH3	–	–	–	–	–	nd	nr	[38]

GH5	1.6	1.1	1.1	–	3.8	nd	nr	[38]

GH32	–	–	–	–	–	nd	InuR	[8, 79]

GH32	2.9	2.0	1.9	5.2	4.1	nd	InuR	[8]

GH28	2.6	−2.3	–	2.2	−2.1	nd	GaaR	[15, 34, 80]

GH32	–	–	–	–	–	nd	InuR	[9, 81, 82]


Year	Public Hospitals	Public medic patients

	Outpatients (95% CI)	# of hospitalizations


Surface material	SBS	ARI

Enamel	Chi-square test	18.512	11.686

 Df	2	2

Asymptotic significance	0.000	0.003

SR Adoro	Chi-square test	0.281	1.636

Df	2	2

Asymptotic significance	0.869	0.441

Filtek Supreme XTE	Chi-square test	20.847	14.017

Df	2	2

Asymptotic significance	0.000	0.001

Wisil	Chi-square test	6.970	6.444

Df	2	2

Asymptotic significance	0.031	0.040

Dispersalloy	Chi-square test	9.223	6.691

Df	2	2

Asymptotic significance	0.010	0.035

Herador	Chi-square test	3.583	8.561

Df	2	2

Asymptotic significance	0.167	0.014

e.max Press	Chi-square test	23.086	11.600

Df	2	2

Asymptotic significance	0.000	0.003

ZirCAD	Chi-square test	16.423	15.612

Df	2	2

Asymptotic significance	0.000	0.000

Mark II	Chi-square test	9.762	19.815

Df	2	2

Asymptotic significance	0.008	0.000

Surface material	SBS	ARI

e.max Press	Asymptotic significance	0.000	0.003

ZirCAD	Chi-square test	16.423	15.612

Df	2	2

Asymptotic significance	0.000	0.000

Mark II	Chi-square test	9.762	19.815

Df	2	2

Asymptotic significance	0.008	0.000


Year	Number of districts	Districts reporting at least one suspected case	Number of suspected cases reported	Blood specimens collected	Confirmed cases	Districts with confirmed cases

	n	 n 	 % 	n	 n 	 % 	 n 	 %

2003	144	52 	36.1	156	156	100	3	1.3	Bafia, Méri, Ntui

2004	159	80 	50.3	434	434	100	2	0.5	Ngaoundéré Rural

2005	159	88 	55.3	831	831	100	2	0.2	Yoko

2006	167	114	68.2	859	859	100	1	0.2	Messamena


Variable	Univariate	Multivariate

p value	p value	HR (95% CI)


Type of ZnO nanostructure	Turn-on field (V μm-1)	Threshold field (V μm-1)	β

Leaf-like (30 min)	2.94	4.35	2,800

Long NWs arrays (60 min)	3.69	5.72	2,526

Needle-like	3.87	5.65	2,284


Patient no.	CSF leakage	Leakage pattern	Location of CSF leakage	Exact location of CSF leakage

1	+	Pseudodiverticular	Left T11/12	+

2	+	Gray rim	L1	+

3	−		−	−

4	+	Gray rim	T12/L1	+

5	+	Pseudodiverticular	Left L2/3 and L3/4	+

6	+	Gray rim	T3	+

7	+	Gray rim	From C5/6 to L1/2	Extensive

8	+	Gray rim	From C1/2 to T10/11	Extensive

9	+	Pseudodiverticular	Right L3/4 and L4/5	+

10	+	Gray rim	L4/5/S1	+

11	+	Gray rim and pseudodiverticular	From T12 to L2	Extensive

12	+	Gray rim	From cervical to upper T-spine	Extensive

13	+	Gray rim	T-spine	Extensive

14	+	Pseudodiverticular	Both T11/12	+

15	+	Gray rim	C5/6/7 and T7/8/9	Extensive

16	+	Pseudodiverticular	Right C5/6	+

17	+	Gray rim	T5/6	+

18	+	Gray rim and pseudodiverticular	From C4 to T4	Extensive

CSF leakage	Leakage pattern	Location of CSF leakage	Exact location of CSF leakage

+	Pseudodiverticular	Left T11/12	+

+	Gray rim	L1	+

−		−	−

+	Gray rim	T12/L1	+

+	Pseudodiverticular	Left L2/3 and L3/4	+

+	Gray rim	T3	+

+	Gray rim	From C5/6 to L1/2	Extensive

+	Gray rim	From C1/2 to T10/11	Extensive

+	Pseudodiverticular	Right L3/4 and L4/5	+

+	Gray rim	L4/5/S1	+

+	Gray rim and pseudodiverticular	From T12 to L2	Extensive

+	Gray rim	From cervical to upper T-spine	Extensive

+	Gray rim	T-spine	Extensive

+	Pseudodiverticular	Both T11/12	+

+	Gray rim	C5/6/7 and T7/8/9	Extensive

+	Pseudodiverticular	Right C5/6	+

+	Gray rim	T5/6	+

+	Gray rim and pseudodiverticular	From C4 to T4	Extensive


Variable

Gender	Men

women

Residence:	Rural

Urban

Age in years:	≤30

31–45

46–60

≥61

Marital status:	Single

Married

Divorced/widowed

Occupation:	Farmer

Employed

Housewife

Retirement pension

Merchants

Monthly income:	No income/dependent

<1000 birr

1001–2000 birr

>2001 birr

BMI, Kg/m2:	Normal (18.5–24.9)

Underweight (<18.5)

Overweight (25–29.9)

Obese (≥30)

Duration since the diagnosis of HTN	<5 years

6–10 years

>11 years

Doing exercises regularly:	Yes

No

FHCD	No

Diabetes

Hypertension

Intensity of Physical activity:	Low

Moderate

High


Instrument	Unprepared apical area (%)	Unprepared coronal area (%)

Mean ± SD	Min-Max	Mean ± SD	Min-Max

ProTaper Next	11.03 ± .96	10.11–12.8	55.70 ± 1.25	53.26–57.19

WaveOne	12.06 ± 1.21	9.25–13.10	55.53 ± 1.01	53.48–57.24

P value	.683c	.684c

Instrument

ProTaper Next

WaveOne

P value


Heart evaluation parameters	CRT	IMRT

Average maximum heart dose (cGy)	5295.26	5209.87

Range (cGy)	4858.3–5743.8	4895.17–5862.8

P-value	0.08	0.08

Heart evaluation parameters	CRT	IMRT

Average maximum hear	52	52


	All studies (n = 102)	Randomized trials (n = 25)	Nonrandomized studies (n = 77)

Number of participants	66 386	7172	59 214

Age range of participants (years)	18–99	29–89	18–99

Number of participating centres (%)

Single	58 (57)	13 (52)	45 (58)

Multiple	44 (43)	12 (48)	32 (42)

IRB or ethical approval reported (%)	52 (51)	14 (56)	38 (49)

Tumour site (%)

Colon	10 (9)	2 (8)	7 (9)

Rectum	54 (53)	11 (44)	44 (55)

Mixed colon and rectum	38 (38)	12 (48)	26 (34)

Surgical approach (%)

Laparoscopy	1 (1)	0	1 (1)

Hand‐assisted laparoscopy	0	0	0

Open	5 (5)	1 (4)	4 (5)

Mixed	13 (12)	9 (36)	5 (6)

Not reported or incomplete information reported	83 (81)	15 (60)	67 (87)

Neoadjuvant treatmenta (%)

Radiotherapy alone	20 (20)	9 (36)	11 (14)

Chemotherapy alone	0	0	0v (0.0)

Chemoradiotherapy	22 (22)	3 (12)	18 (24)

None	7 (7)	1 (4)	6 (8)

Not reported or incomplete information reported	53 (51)	12 (48)	42 (54)

Adjuvant treatmenta (%)

Chemotherapy or chemoradiotherapy	56 (55)	16 (64)	40 (52)

None	0	0	0

Not reported or incomplete information reported	46 (45)	9 (36)	37 (48)

Number of PROMs reported

1	43	10	33

2	47	12	35

3	6	2	4

4	4	1	3

5	2	0	2

Number of participants

Age range of participants (years)

Number of participating centres (%)

Single

Multiple

IRB or ethical approval reported (%)

Tumour site (%)

Colon

Rectum

Mixed colon and rectum

Surgical approach (%)

Laparoscopy

Hand‐assisted laparoscopy

Open

Mixed

Not reported or incomplete information reported

Neoadjuvant treatmenta (%)

Radiotherapy alone

Chemotherapy alone

Chemoradiotherapy

None

Not reported or incomplete information reported

Adjuvant treatmenta (%)

Chemotherapy or chemoradiotherapy

None

Not reported or incomplete information reported

Number of PROMs reported

1

2

3

4

5


Figure #	Algorithms Used	Initial Benefit	Acquired Benefit	Lost Benefit	Overall Distance	Solution Time (s)

11a	Greedy TA Heuristic MP	21,000	9479	11,521	2446	1.85

11b	Greedy TA Heuristic MP	21,000	9440	11,560	2462	2.73

Al	Initial Benefit	Acquire	Lost	Over	Solution Tim

Figure #	gorithms Used		d Benefit	 Benefit	all Distance	e (s)

11a	Greedy TA Heuristic MP	21,000	9479	11,521	2446	1.85

11b	Greedy TA Heuristic MP	21,000	9440	11,560	2462	2.73


Construct	Transgene	Progeny	n

	ebEx498	92 ± 16	11

	xyEx175	123 ± 15	10

	xyEx177	115 ± 17	11

	xyEx1	2 ± 1	10

	xyEx2	1 ± 0.62	9

	xyEx3	6 ± 2	9

	xyEx27	11 ± 4	10

Construct	Transgene	Progeny	n

	xyEx30	8 ± 4	10

	xyEx34	17 ± 4	10

	xyEx36	83 ± 15	9

	xyEx37	110 ± 10	8

	xyEx41	123 ± 15	10

	N2 (wild type)	185 ± 5	10

	spe-42(tn1231)	0	24

	spe-42(tm2421)	0	15


Epigenetic discovery	Health promotion research innovation domains	Example translational research questions

Individual variation in whether risk exposures negatively influence gene expression	Improving motivational potency of health communications	Evaluating relative benefit of validating beliefs about individual variability in extent of harm produced by risk behaviors on motivation

Intervention adherence can prompt measurable gene expression	Intervention targeting and tailoring	Comparative effectiveness of targeting relapse prevention approach based on gene expression profile following intervention participation

New technology to measure epigenetic processes (e.g., methylation) in saliva and blood samples	Novel biomarkers of intervention impact	Evaluate intervention adherence on gene expression in randomized effectiveness trials


	MCAA+	MCAA−	NHS	PLG+

Age (mean)	61.0	59.2	58.7	59.6


Patient	1	2	3

Age(year)	47	39	48

Follow-up(month)	70	54	5

Outcome	Favorable	Favorable	Favorable

Pre-operation upper-limb blood pressure(mm Hg)	125/65	135/65	145/50

Pre-operation lower-limb blood pressure(mm Hg)	100/55	110/50	125/45

Post-operation upper-limb blood pressure(mm Hg)	125/65	125/80	130/80

Post-operation lower-limb blood pressure(mm Hg)	130/70	130/80	130/75

Patient	1	2	3

Post-operation upper-limb blood pressure(mm Hg)	125/65	125/80	130/80

Post-operation lower-limb blood pressure(mm Hg)	130/70	130/80	130/75


Characteristic§	Levels of sCD40L

	High	Medium-Low	p

	No.	(%)	No.	%


	df	AIC	BIC	logLik

m.rel.index	8	2043373	2043457	−1021678

	df	AIC	BIC	logLik

m.freq.index	8	2043326	2043410	−1021655


Characteristic	Number (%)

Season

Spring(January–March)	161(23.5%)

Summer(April–June)	252(36.8%)

Autumn(July–September)	123(18.0%)

Winter(October–December)	148(21.6%)

Clinical Symptoms

Nausea	60(10.8%)

Vomiting	114(20.6%)

Abdominal pain	268(48.3%)

Fever(> 37.2 °C)	97(17.4%)

others	16(2.9%)


 	Serology (serologicmarkers)∗	Endoscopy of duodenum (mucosal morphologic alternations∗∗)	Genotype (genetic markers)

 	IgA anti-tissue transglutaminase antibodies (IgA anti-tTG, IgG anti-tTG antibodies)	Mucous membrane thickness	 HLA-typing

Anti-endomysial antibodies (AEA, IgA-anti-EMA)	Villus height

Anti-deamidated gliadin peptide (IgA anti-DGP, IgG anti-DGP)	Crypt depth

 	Crypt-villus ratio

Limitations	Specificity and sensitivity of test method; the active period of the disease; long-term gluten-free diet	Similar histological pattern of some other diseases; long-term gluten-free diet	—

	Anti-deamidated gliadin peptide (IgA anti-DGP, IgG anti-DGP)	Crypt depth	HLA-typing

	Crypt-villus ratio

Limitations	Specificity and sensitivity of test method; the active period of the disease; long-term gluten-free diet	Similar histological pattern of some other diseases; long-term gluten-free diet	—


	Caf1	Ccr4

	Gene	Synonyms	Gene	Synonyms

Saccharomyces cerevisiae	POP2	CAF1	CCR4	FUN27, NUT21

Schizosaccharomyces pombe	caf1	pop2	CCR4

Caenorhabditis elegans	CCF-1		CCR-4

Drosophila melanogaster	Pop2	CAF1	Twin	CCR4

Xenopus laevis	Cnot7	caf1, caf-1	Cnot6	CCR4A

	Cnot8	pop2, calif	Cnot6l	CCR4B

Danio rerio	Cnot7	zgc:153168	Cnot6	Zgc:65822

	Cnot8	zgc:63844	Cnot6l	Zgc:111987

Mus musculus	Cnot7	Caf1	Cnot6

	Cnot8		Cnot6l

Homo sapiens	CNOT7	Caf1; Caf1a	CNOT6	Ccr4; Ccr4a

	CNOT8	Pop2; Calif; Caf1b	CNOT6L	Ccr4-like;

	Caf1

	Gene

Saccharomyces cerevisiae	POP2

Schizosaccharomyces pombe	caf1

Caenorhabditis elegans	CCF-1

Drosophila melanogaster	Pop2

Xenopus laevis	Cnot7

	Cnot8

Danio rerio	Cnot7

	Cnot8

Mus musculus	Cnot7

	Cnot8

Homo sapiens	CNOT7

	CNOT8

Caf1	Ccr4

Synonyms	Gene	Synonyms

CAF1	CCR4	FUN27, NUT21

pop2	CCR4

	CCR-4

CAF1	Twin	CCR4

caf1, caf-1	Cnot6	CCR4A

pop2, calif	Cnot6l	CCR4B

zgc:153168	Cnot6	Zgc:65822

zgc:63844	Cnot6l	Zgc:111987

Caf1	Cnot6

	Cnot6l

Caf1; Caf1a	CNOT6	Ccr4; Ccr4a

Pop2; Calif; Caf1b	CNOT6L	Ccr4-like;


	Lower-middle income (906–3595)	818 (69.9)	410 (72.8)

	Upper-middle income (3596–11115)	7 (0.6)	3 (0.5)

Employment status

	Unemployed/ sacked from the present job/ Retired	78 (6.7)	25 (4.4)	0.001

	Office work/ Business/ Skilled labour	104 (8.9)	85 (15.1)

	House maker/farmer	846 (72.3)	306 (54.4)

	Rickshaw puller/day labour/ Others	142 (12.1)	147 (26.1)


Factors	Have you ever attended VCT (N (%))

	Yes	No	χ2	p-value

Religion

Protestant	36(29.3)	87(70.7)	5.6	0.13

Catholic	39(37.1)	66(62.9)

Muslims	21(47.7)	23(52.3)

Others	11(29.7)	26(70.3)

Professional groups

Medical students (MD)	35(32.7)	65(32.2)	0.98	0.80

Nursing	33(30.8)	60(29.7)


	Total

No. of patients	394

Age (years)

Mean ± SD	57.0 ± 12.8

Range	28-94


Patient number	Patient age	Early or late infection	Procedure	Time after first washout that NPWT was applied	Duration of NPWT	Number of NPWT changes	Long-term outcome

1	17 years	Late	Corrective surgery for severe scoliosis	0 days	21 days	3	Metalwork retained, no infection

2	46 years	Early	Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection

3	43 years	Early	Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection

4	41 years	Early	Instrumented anterior lumbar spine fusion	0 days	15 days	2	Metalwork retained, no infection

5	72 years	Early	Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection

Patient number	Patient age	Early or late infection

1	17 years	Late

2	46 years	Early

3	43 years	Early

4	41 years	Early

5	72 years	Early

Procedure	Time after first washout that NPWT was applied	Duration of NPWT	Number of NPWT changes	Long-term outcome

Corrective surgery for severe scoliosis	0 days	21 days	3	Metalwork retained, no infection

Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection

Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection

Instrumented anterior lumbar spine fusion	0 days	15 days	2	Metalwork retained, no infection

Instrumented lumbar spine fusion	0 days	14 days	2	Metalwork retained, no infection


MAA Category	Commercial Agreement	Payment for Performance Agreement	Coverage with Evidence Development

Contract type	• Discount-based contract	• Permanent risk-shifting agreement (outcomes guarantee/insurance) applied on a per-patient basis	• Provisional agreement until new, clearly specified evidence develops from a cohort of patients

Collection and analysis of patient health outcomes data by the payer	• None	• Per patient	• Cohort of patients

Timeframe of the MAA	• Permanent/not linked to final decision-making	• Permanent/not linked to final decision-making based on new robust evidence	• Temporary/provisional until new evidence allows making a final decision

Underlying concept (payer perspective)	• Reducing pharmaceutical expenditure	• Avoiding inefficient expenditure on treating patients who do not respond to a drug and who cannot be identified ex ante (by permanently linking the payment to drug's performance in individual patients)	• Reducing uncertainty about drug's real-life effectiveness (by linking a final HTA, reimbursement and/or pricing decision to drug's performance in a cohort of patients, during a defined test period)

Examples	• Flat price per patient (regardless of the number of doses administered)• Cost Sharing• Rebate• Discount	• Payment for performance• Pay-back for non performance	• Temporary coverage on a condition that new evidence reduces uncertainty about a pre-specified health outcome:- Real-life effectiveness- Higher efficacy in a pre-specified subpopulation of patients- Long-term effect- Improved patient's adherence- Reduction of use of health care resources (e.g. hospitalization)

MAA Category	Commercial Agreement	Payment for Performance Agreement	Coverage with Evidence Development

Timeframe of the MAA	• Permanent/not linked to final decision-making	• Permanent/not linked to final decision-making based on new robust evidence	• Temporary/provisional until new evidence allows making a final decision

Underlying concept (payer perspective)	• Reducing pharmaceutical expenditure	• Avoiding inefficient expenditure on treating patients who do not respond to a drug and who cannot be identified ex ante (by permanently linking the payment to drug's performance in individual patients)	• Reducing uncertainty about drug's real-life effectiveness (by linking a final HTA, reimbursement and/or pricing decision to drug's performance in a cohort of patients, during a defined test period)

Examples	• Flat price per patient (regardless of the number of doses administered)• Cost Sharing• Rebate• Discount	• Payment for performance• Pay-back for non performance	• Temporary coverage on a condition that new evidence reduces uncertainty about a pre-specified health outcome:- Real-life effectiveness- Higher efficacy in a pre-specified subpopulation of patients- Long-term effect- Improved patient's adherence- Reduction of use of health care resources (e.g. hospitalization)


	All patients	Cases	Control

Samples	10,324	6,564	5,072b

Identified CNVs	14,226a	9,186	495,916

Type of CNVs:

Loss	7,554	5,101	343,489

Gain	6,672	4,085	152,427

Average CNV length (Kb)	3,336	3,014	31

Type of inheritance:

De novo constitutive	14,501	2,454

Inherited from normal parent	9,345	1,945

Inherited from parent with similar phenotype to child	1,345	240

Unknown	21,946	3,638

	All patients	Cases

Samples	10,324	6,564

Identified CNVs	14,226a	9,186

Type of CNVs:

Loss	7,554	5,101

Gain	6,672	4,085

Average CNV length (Kb)	3,336	3,014

Type of inheritance:

De novo constitutive	14,501	2,454

Inherited from normal parent	9,345	1,945

Inherited from parent with similar phenotype to child	1,345	240

Unknown	21,946	3,638


 	Flexion	Extension

Pre-operation	13 months after the operation	18 months after the operation	Pre-operation	13 months after the operation	18 months after the operation

Left hip	0°-25°	0°-85°	0°-110°	Flexion deformity	0°-15°	0°-15°

Right hip	0°-15°	0°-80°	0°-105°	0°-10°	0°-10°

Left knee	0°-15°	0°-100°	0°-125°	0°	0°

Right knee	0°-10°	0°-90°,	0°-127°	0°	0°

	Flexion

Pre-operation

Left hip	0°-25°

Right hip	0°-15°

Left knee	0°-15°

Right knee	0°-10°

Flexion	Extension

13 months after the operation	18 months after the operation	Pre-operation	13 months after the operation	18 months after the operation

0°-85°	0°-110°	Flexion deformity	0°-15°	0°-15°

0°-80°	0°-105°	0°-10°	0°-10°

0°-100°	0°-125°	0°	0°

0°-90°,	0°-127°	0°	0°


Trait	Description (ability assessed)	CLDRC-RD (564)	UK-RD (958)	SLIC (498)	CLDRC-ADHD (163)

WRead	Reading real words	x (0.918)	x (0.918)	x (0.902)	x (0.871)

WSpell	Spelling real words	x (0.813)	x (0.852)	x (0.862)	x (0.764)

PD	Ability to convert letter strings into sounds, according to given phonetic rules	x (0.895, 0.861)*	x (0.809)		x (0.821, 0.729)*

PA	Ability to recognize and manipulate speech sounds (phonemes)	x (0.801)	x†		x (0.744)

OC	Ability to recognize a word as an orthographic unit and to retrieve the corresponding phonological form	x (0.764)	x (0.888)		x (0.644)

NWR	Ability to repeat nonsense words orally presented	x (0.493)		x (0.665)	x (0.355)

ELS	Sentence recalling and production (expressive domain of language)			x (0.856)

RLS	Listening and auditory comprehension (receptive domain of language)			x (0.837)

VIQ	Verbal reasoning	x	x	x	x

PIQ	Logical reasoning	x	x	x	x

PC1	Common variance in reading and language skills	544	914	245	159

IQ-adjusted PC1	Common variance in reading and language skills, not shared with general cognitive abilities	544	878	245	159

Trait	Description (ability assessed)	CLDRC-RD (564)	UK-RD (958)	SLIC (498)	CLDRC-ADHD (163)

RLS	Listening and auditory comprehension (receptive domain of language)			x (0.837)

VIQ	Verbal reasoning	x	x	x	x

PIQ	Logical reasoning	x	x	x	x

PC1	Common variance in reading and language skills	544	914	245	159

IQ-adjusted PC1	Common variance in reading and language skills, not shared with general cognitive abilities	544	878	245	159


 	T-cell development	Naive T-cell homeostasis	T-cell activation	T-cell differentiation	T-cell memory	References

Slc7a5–/– mice	No	No	T-cell activation↓	Th1 and Th17 cells↓	Not available	11

Slc1a5–/– mice	No	(1) For young micea: No (2) For older miceb: CD4+ T cells↓CD44loCD62Lhi CD4+ T cells↑	Activation of mTORC1 in T cellsc↓	Th1 and Th17 cells↓	(1) For young micea: No(2) For older miceb: Memory CD4+ T cells↓	10

Slc6a1–/– mice	No	No	IL-2 secretion and CD69 expression in T cellsc ↑	Th1 cells↑	Not available	9, 71


Term	Number of medications	Number of studies	References

Polypharmacy	≥ 2 for > 240 days (long term)	1	[101]

	≥ 5 medications in the same month	1	[103]

	> 5 medications for ≥ 90 days	1	[104]

	≥ 5 medications in the same quarter of a year	1	[105]

	≥ 5 medicines at hospital discharge	1	[106]

	5 to 9 medicines on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)	1	[107]

	5 to 9 medications for ≥ 90 days	1	[108]

	5 to 9 medicines during hospital stay	1	[109]

	≥ 10 medicines during hospital stay	1	[110]

Major polypharmacy	≥ 10 on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)	1	[107]

Hyperpolypharmacy	≥ 10 medications for ≥90 days	1	[108]

Excessive polypharmacy	≥ 10 medications in the same quarter of a year	1	[105]

	≥ 10 medications during hospital stay	1	[109]

Persistent polypharmacy	≥ 5 medications for 181 days	1	[52]

Chronic polypharmacy	≥ 5 medications in 1 month for 6 months (consecutive or not) in a year	1	[111]

Term	Number of medications	Number of studies

Polypharmacy	≥ 2 for > 240 days (long term)	1

	≥ 5 medications in the same month	1

	> 5 medications for ≥ 90 days	1

	≥ 5 medications in the same quarter of a year	1

	≥ 5 medicines at hospital discharge	1

	5 to 9 medicines on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)	1

	5 to 9 medications for ≥ 90 days	1

	5 to 9 medicines during hospital stay	1

	≥ 10 medicines during hospital stay	1

Major polypharmacy	≥ 10 on the day of maximum number of prescriptions of the study year (on the day of the study year when the number of medications prescribed was highest)	1

Hyperpolypharmacy	≥ 10 medications for ≥90 days	1

Excessive polypharmacy	≥ 10 medications in the same quarter of a year	1

	≥ 10 medications during hospital stay	1

Persistent polypharmacy	≥ 5 medications for 181 days	1

Chronic polypharmacy	≥ 5 medications in 1 month for 6 months (consecutive or not) in a year	1


Abdominal Distension	5/16	0/12	0.18

Respiratory Distress	13/16	10/12	0.73

Lethargy	8/16	5/12	0.67

Syncope	2/16	4/12	0.64

Exercise Intolerance	8/16	6/12	1.0


Water Microbe	Amplified NuclearRibosomal Regions	Primer Sets (from 5' to 3')	PCR Program

Bacteria [19,20]	16S rRNA V4-V5 region	515F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT	95°C for 2 min, 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min

Fungi [21]	Internal transcribedspacer-1 (ITS1) region	1737F:GGAAGTAAAAGTCGTAACAAGG2043R:GCTGCGTTCTTCATCGATGC	95°C for 1 min, 30 cycles of 95°C for 10 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min

Water Microbe	Amplified NuclearRibosomal Regions	Primer Sets (from 5' to 3')	PCR Program

Bacter	16S rRNA V4-V5 reg	51	95°C for 2

ia [19,20]	ion	5F: GTGCCAGCMGCCGCGGTAA907R: CCGTCAATTCCTTTGAGTTT	 min, 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min

Fungi [21]	Internal transcribedspacer-1 (ITS1) region	1737F:GGAAGTAAAAGTCGTAACAAGG2043R:GCTGCGTTCTTCATCGATGC	95°C for 1 min, 30 cycles of 95°C for 10 s, 55°C for 30 s, 72°C for 30 s, with a final extension at 72°C for 5 min


whale	age/sex	year	tag duration (days)	min. latitude (° S)	max. SST (°C)

1	adult/female	2009	08 Jan–16 Jan (9)	64	2.3

2	adult/female	2009	14 Jan–27 Jan (14)	67	2.1

3	adult/female	2009	15 Jan–31 Jan (17)	60	2.9

4	adult/female	2009	24 Jan–13 Feb (21)	51	11.2

5	subadult/male	2010	13 Feb–24 Feb (12)	63	2.1

6	adult/female	2010	13 Feb–21 May (98)	30	22.4

7	adult/female	2010	13 Feb–01 Jun (109)	30	22.4

8	adult/male	2011	13 Jan–31 Jan (19)	67	1.8

9	adult/female	2011	13 Jan–25 Feb (44)	37	22.9

10	adult/female	2011	15 Jan–16 Apr (93)	36	20.9

11	adult/female	2011	15 Jan–22 Apr (99)	30	24.2

12	adult/female	2011	24 Jan–13 Feb (21)	65	1.9

whale	age/sex	year	tag duration (days)	min. latitude (° S)	max. SST (°C)

8	adult/male	2011	13 Jan–31 Jan (19)	67	1.8

9	adult/female	2011	13 Jan–25 Feb (44)	37	22.9

10	adult/female	2011	15 Jan–16 Apr (93)	36	20.9

11	adult/female	2011	15 Jan–22 Apr (99)	30	24.2

12	adult/female	2011	24 Jan–13 Feb (21)	65	1.9


Age (yrs)	Weight (kg)	Gender	Ethnicity	Indication	Target INR	Drug Interaction(s)	Therapeutic warfarin dose (mg/d)	Reference

69	79.8	Female 	Japanese	AFib	1.5–20	NR	0.5	[8]

71	82	Male 	White	AFib	2.0–3.0	Amiodarone 	0.9	[11]

58	70	Male 	Japanese	AFib	NR	Propafenone 	0.25–0.75	[12]

68	70	Female 	Chinese	AFib	2.0–3.0	NR	0.63	[13]

50	88	Male 	Chinese	AFib	2.0–3.0	NR	1.25	[13]

74	54	Female 	White	AFib	2.0–3.0	Amiodarone/Atorvastatin	0.5	Present case

Age (yrs)	Weight (kg)	Gender	Ethnicity	Indication	Target INR	Drug Interaction(s)	Therapeutic warfarin dose (mg/d)	Reference

50	88	Male	Chinese	AFib	2.0–3.0	NR	1.25	[13]

74	54	Female	White	AFib	2.0–3.0	Amiodarone/Atorvastatin	0.5	Present case


	N	%

Clozapine	9	39

Other antipsychotics	14	61

 Traditional antipsychotics	6	26

 Atypical antipsychotics	8	35

Mood stabilizers	5	22

Clozapine dose	481 ± 218 mg (range 300 - 900)

Serum level of clozapine	1671 ± 1164 μmol/l (range 326 - 3333)

	N

Clozapine	9

Other antipsychotics	14

Traditional antipsychotics	6

Atypical antipsychotics	8

Mood stabilizers	5

Clozapine dose	481 ± 218 mg (range 300 - 900)

Serum level of clozapine	1671 ± 1164 μmol/l (range 326 - 3333)


Barrier	1st Barrier	2nd Barrier	3rd Barrier	Total

Freq	%	Freq	%	Freq	%	N

Delay before care is received	59	10.9	35	6.5	9	1.7	103

Long distance to treatment centres	6	1.1	24	4.5	11	2	41

Financial challenges	68	12.6	24	4.4	19	3.5	111

Job insecurity	14	2.6	7	1.3	5	0.9	26

No challenge	198	36.7	350	64.8	418	77.4	966

Shortage of drugs and other commodities	72	13.3	34	6.3	12	2.2	118

Fear of side effects	26	4.8	8	1.5	2	0.4	36

Stigmatisation	7	1.3	6	1.1	3	0.6	16

Total	540	100	540	100	540	100	1620

Barrier	1st Barrier

Freq	%

Delay before care is received	59	10.9

Long distance to treatment centres	6	1.1

Financial challenges	68	12.6

Job insecurity	14	2.6

No challenge	198	36.7

Shortage of drugs and other commodities	72	13.3

Fear of side effects	26	4.8

Stigmatisation	7	1.3

Total	540	100


CRP, mg/L	2.2 (2.0, 2.4)	-

CRP > 5 mg/L	189 (24.6)	-

Malaria antigenemia (elevated HRP2) 8	97 (12.6)	-


Parameters	Lead (Pb)	Cadmium (Cd)	Zinc (Zn)	Iron (Fe)	References

Water concentration (ppm)	0.33 ± 0.03	0.02 ± 0.00*	0.01 ± 0.00**	2.61 ± 0.07**	This study

Liver concentration (ppm)	0.35 ± 0.04	0.04 ± 0.00*	2.17 ± 0.30**	11.66 ± 1.32**	This study

Bioaccumulation factor	1.06	2.00	217.00	4.46	This study

Maximum acceptable water limit (ppm)	0.01	0.003	3.00	0.30	NIS (2007)

0.01	0.01	5.00	0.30	WHO (2003) [24]

Maximum acceptable liver limit (mgkg-1)	0.01	0.01	5.00	0.30	WHO (2003) [24]


Factor

Na

S

P

Ca

K

Mg

Fe

Al

As

B

Ba

Cd

Co

Cr

Cu

Ga

Ge

Hg

Li

Mn

Ni

Pt

Sr

Ti

Zn

Rb

TCE

pH

Moisture

Longitude

Latitude


Factor	Effect on efficiency	Implications

Decreased morale	Decrease	Increase staff support and supervision, plan for retention, access to ART

Increased experience	Increase	Plan to increase retention to keep experienced staff

Increased training	Increase long term (short-term training time may decrease efficiency)	Plan for quality training on-hire (practical and didactic), continuing education, work to integrate into preclinical education in health services

Staff flexibility	Potentially increase	Provide education and support to encourage staff willing to expand/change roles to increase efficiency of the overall programme

Factor	Effect on efficiency	Implications

Decreased morale	Decrease	Increase staff support and supervision, plan for retention, access to ART

Increased experi	In	Plan to increase retention to keep experience

ence	crease	d staff

Increased training	Increase long term (short-term training time may decrease efficiency)	Plan for quality training on-hire (practical and didactic), continuing education, work to integrate into preclinical education in health services

Staff flexibility	Potentially increase	Provide education and support to encourage staff willing to expand/change roles to increase efficiency of the overall programme


Metabolic syndrome, n (%)	8 (36.36%)	72 (18.37%)	0.0375∗

Cortisol excess screening, n (%)‡	22 (100%)	392 (100%)	—

Confirmation test performed, n (%)§	22 (100%)	264 (67.35%)	—

Aldosterone excess screening, n (%)	22 (100%)	392 (100%)	—

Confirmation test performed, n (%)	22 (100%)	392 (100%)	—


Error type and antimicrobial	Organism	No. of errors	MICa	AST resultb	Breakpointa	Reportable rangea

AXDX	REF	AXDX	REF	S	R	Low	High

Very major errors

Daptomycin	Staphylococcus aureus	1	0.5	≥2	S	NS	1	N/A	0.25	2

Erythromycin	Staphylococcus warneric	1	0.25	≥16	S	R	0.5	8	0.125	16

Cefoxitin (MRSA/MRS)	Staphylococcus epidermidis	4	N/A	N/A	NEG	POS	4	8	4	8

	Staphylococcus haemolyticus	1	N/A	N/A	NEG	POS	4	8	4	8

Erythromycin-clindamycin (MLSb)	Staphylococcus warneri	1	N/A	N/A	NEG	POS	2	4	2	4

Major errors

Ampicillin	Enterococcus faecium	1	16	8	R	S	8	16	2	32

Daptomycin	Enterococcus faecium	1	≥8	2	NS	S	4	N/A	1	8

Doxycyclinec	Staphylococcus hominis subsp. hominis	1	16	4	R	S	4	16	1	32

Staphylococcus aureus	4	≥32	2	R	S	4	16	1	32

Erythromycin	Staphylococcus aureus	1	≥16	0.25	R	S	0.5	8	0.125	16

Cefoxitin (MRSA/MRS)	Staphylococcus epidermidis	1	N/A	N/A	POS	NEG	4	8	4	8

Staphylococcus aureus	1	N/A	N/A	POS	NEG	4	8	4	8

Erythromycin-clindamycin (MLSb)	Staphylococcus epidermidis	1	N/A	N/A	POS	NEG	2	4	2	4

	Staphylococcus warneri	1	N/A	N/A	POS	NEG	2	4	2	4

TMP-SMXc,d	Staphylococcus aureus	1	≥8	2	R	S	2	4	0.5	8

2	≥8	≤0.5	R	S	2	4	0.5	8

2	4	1	R	S	2	4	0.5	8

2	4	≤0.5	R	S	2	4	0.5	8

Staphylococcus lugdunensis	3	4	≤0.5	R	S	2	4	0.5	8

Error type and antimicrobial	Organism	No. of errors	MICa	AST resultb	Breakpointa	Reportable rangea

AXDX	REF	AXDX	REF	S	R	Low	High

Very major errors

Daptomycin	Staphylococcus aureus	1	0.5	≥2	S	NS	1	N/A	0.25	2

Erythromycin	Staphylococcus warneric	1	0.25	≥16	S	R	0.5	8	0.125	16

Cefoxitin (MRSA/MRS)	Staphylococcus epidermidis	4	N/A	N/A	NEG	POS	4	8	4	8

	Staphylococcus haemolyticus	1	N/A	N/A	NEG	POS	4	8	4	8

Erythromycin-clindamycin (MLSb)	Staphylococcus warneri	1	N/A	N/A	NEG	POS	2	4	2	4

Major errors

Ampicillin	Enterococcus faecium	1	16	8	R	S	8	16	2	32

Daptomycin	Enterococcus faecium	1	≥8	2	NS	S	4	N/A	1	8

Doxycyclinec	Staphylococcus hominis subsp. hominis	1	16	4	R	S	4	16	1	32

Staphylococcus aureus	4	≥32	2	R	S	4	16	1	32

Erythromyci	Staphy	1		0.25			0.5		0.	16

n	lococcus aureus		≥16		R	S		8	125

Cefoxitin (MRSA/MRS)	Staphylococcus epidermidis	1	N/A	N/A	POS	NEG	4	8	4	8

Staphylococcus aureus	1	N/A	N/A	POS	NEG	4	8	4	8

Erythromycin-clindamycin (MLSb)	Staphylococcus epidermidis	1	N/A	N/A	POS	NEG	2	4	2	4

	Staphylococcus warneri	1	N/A	N/A	POS	NEG	2	4	2	4

TMP-SMXc,d	Staphylococcus aureus	1	≥8	2	R	S	2	4	0.5	8

2	≥8	≤0.5	R	S	2	4	0.5	8

2	4	1	R	S	2	4	0.5	8

2	4	≤0.5	R	S	2	4	0.5	8

Staphylococcus lugdunensis	3	4	≤0.5	R	S	2	4	0.5	8


	Target population (n = 5)	Key stakeholders (n = 5)

Gender	Male (4)	Male (3)

Age	21–34 years
(mean: 26 years)	23–38 years
(mean: 29 years)

Educational status	Primary (1)	High-school (2)

Secondary (2)	Bachelors (2)

High-school (1)	Masters (1)

Bachelors (1)

Countries visited	Malaysia (2)	n/a

Saudi Arabia (1)

Qatar (1)

UAE (1)

Occupation	Domestic service (1)	Coordinator (1)

Driver (1)	Counselor (2)

Construction (2)	Field worker (2)

Cook (1)

Work experience	3–8 years
(mean: 5.2 years)	1–6 years
(mean: 4.4 years)

	Target population (n = 5)

Gender	Male (4)

Age	21–34 years
(mean: 26 years)

Educational status	Primary (1)

Secondary (2)

High-school (1)

Bachelors (1)

Countries visited	Malaysia (2)

Saudi Arabia (1)

Qatar (1)

UAE (1)

Occupation	Domestic service (1)

Driver (1)

Construction (2)

Cook (1)

Work experience	3–8 years
(mean: 5.2 years)

Key stakeholders (n = 5)

Male (3)

23–38 years
(mean: 29 years)

High-school (2)

Bachelors (2)

Masters (1)

n/a

Coordinator (1)

Counselor (2)

Field worker (2)

1–6 years
(mean: 4.4 years)


 	No. (%)

State of health

Good	349 (37.0)

Poor	595 (63.0)

Emotional status

Blank	144 (15.3)

Unhappy (ever)	99 (10.5)

Ordinary	343 (36.3)

happy	348 (36.9)

No response	10 (1.1)

Smoking

No	925 (98.0)

<5 cigarettes per day	11 (1.2)

6 ~ 10 cigarettes per day	5 (0.5)

11 ~ 20 cigarettes per day	3 (0.3)

Alcohol use

No	856 (90.7)

<1 time per week	63 (6.7)

1 ~ 2 times per week	18 (1.9)

3 ~ 6 times per week	6 (0.6)

≥1 time per day	1 (0.1)

Religion

No	580 (61.4)

Yes	364 (38.6)

Exercise regularly

No	487 (51.6)

Yes	457 (48.4)

Exercise duration (years)

<3	93 (9.9)

3 ~ 5	116 (12.3)

6 ~ 10	118 (12.5)

>10	74 (7.8)

No response	46 (4.9)

	No. (%)

Ordinary	343 (36.3)

happy	348 (36.9)

No response	10 (1.1)

Smoking

No	925 (98.0)

<5 cigarettes per day	11 (1.2)

6 ~ 10 cigarettes per day	5 (0.5)

11 ~ 20 cigarettes per day	3 (0.3)

Alcohol use

No	856 (90.7)

<1 time per week	63 (6.7)

1 ~ 2 times per week	18 (1.9)

3 ~ 6 times per week	6 (0.6)

≥1 time per day	1 (0.1)

Religion

No	580 (61.4)

Yes	364 (38.6)

Exercise regularly

No	487 (51.6)

Yes	457 (48.4)

Exercise duration (years)

<3	93 (9.9)

3 ~ 5	116 (12.3)

6 ~ 10	118 (12.5)

>10	74 (7.8)

No response	46 (4.9)


Reason of Intake	Cat	Dog

Stray	100 (80.6%)	58 (47.5%)

People Issues (allergic, relocating, etc.)	5 (4.0%)	16 (13.1%)

Deceased Caretaker	3 (2.4%)	1 (0.8%)

Negligence	2 (1.6%)	0 (0%)

Abandoned (chip and no reclaim)	0 (0%)	9 (7.4%)

Animal Illness	13 (10.5%)	27 (22.1%)

Behavior	1 (11.9%)	11 (9.0%)


Target	Species	Dilution	Reference

Primary antibodies

 Nrf2	Rabbit	1:100	ab31163; Abcam, UK

 AhR	Rabbit	1:200	sc-5579; H-211; Santa Cruz, Heidelberg, Germany

Secondary antibodies

 Anti-rabbit	Goat	1:2000	AS09 633; Agrisera, Vännas, Sweden

Target	Species	Dilution	Reference

ndary antibodies

Anti-rabbit	Goat	1:2000	AS09 633; Agrisera, Vännas, Sweden


Tumor and normal cells	Cis-3M-RESIC50 (μM)*	ResveratrolIC50 (μM)*

Unstimulated human peripheral T cells	>10.0	N.D

PHA-stimulated human peripheral T cells**	0.23	N.D

Human acute T cell leukemia Jurkat E6.1	0.07	110.1

Human acute T cell leukemia Jurkat (JT/Neo)	0.08	97.5

Human acute T cell leukemia Jurkat (JT/BCL-2)	>10.0	>250.0

Human monoblastoid U937	0.08	86.6

Human promyelocytic leukemia HL-60	0.08	60.5

Human cervical carcinoma HeLa	0.17	193.4

Tumor and normal cells

Unstimulated human peripheral T cells

PHA-stimulated human peripheral T cells**

Human acute T cell leukemia Jurkat E6.1

Human acute T cell leukemia Jurkat (JT/Neo)

Human acute T cell leukemia Jurkat (JT/BCL-2)

Human monoblastoid U937

Human promyelocytic leukemia HL-60

Human cervical carcinoma HeLa


Variable	Categories	Unadjusted Odd ratio (CI)

Fistula size	Large (> 3 cm)	5.33(0.93-30.50)

	Medium (1-3 cm)	0.63(1.39-2.86)

	Small (< 3 cm)	1

Level of vaginal scarring	Moderate severe	NA

	Mild or no scarring	1

Urethral involvement	Circumferential	10.50 (1.39-79.13)*

	Partial/Juxta	5 (1.14-22.00)*

	Urethral involvement

	No urethral involvement	1

Class of Fistula	Type II b	5.56(1.34-23.02)*

	Type II a	O.625(0.06-6.30)

	Type I	1

Previous Repair	Yes	4.8(1.27-18.11)*

	No	1

Variable	Categories	Unadjusted Odd ratio (CI)

	Urethral involvement

	No urethral involvement	1

Class of Fistula	Type II b	5.56(1.34-23.02)*

	Type II a	O.625(0.06-6.30)

	Type I	1

Previous Repair	Yes	4.8(1.27-18.11)*

	No	1


	Adult n (%) (n = 186)a	Paediatric n (%) (n = 17)a	p-value

Pulmonary TB	125 (67)	14 (82)	0.198

 Multidrug-resistant TB	7 (6)	2 (14)	0.099

Method TB detected

 Screening performed at arrival	35 (19)	7 (41)	0.029

 During contact tracing of another TB patient	14 (8)	4 (24)	0.026

 Sought care for symptoms or by chance	137 (74)	6 (35)	<0.01

Time from arrival to Finland to diagnosis of TB

< 3 months	39 (21)	9 (53)	<0.01

 3–23 months	51 (27)	4 (24)	0.73

≥ 24 months	80 (43)	4 (24)	0.119

 Unknown	16 (9)	0 (0)	0.254

Person had resided in

 Reception centre in Finland	27 (15)	8 (47)	<0.01

 Refugee camp abroad	25 (13)	5 (29)	0.076

No TB-related symptoms	40 (22)	10 (59)	<0.01

	Adult n (%) (n = 186)a	Paediatric n (%) (n = 17)a	p-value

Reception centre in Finland	27 (15)	8 (47)	<0.01

Refugee camp abroad	25 (13)	5 (29)	0.076

No TB-related symptoms	40 (22)	10 (59)	<0.01


ISTH 	Predicted score fr	Predicted score from PT + AP	Predicted score fro


 	All participants(N = 2,467)

Age, years	58.3 (15.7)

Sex, women, n	1,438 (58.3%)

Regular exercise,an	831 (33.8%)

Smoking	Current smoker, n	381 (15.5%)

 	Ex-smoker, n	460 (18.7%)

Alcohol consumption, g/week	72.1 (133.7)

Body mass index, kg/m2	23.1 (3.4)

Systolic blood pressure, mm Hg	132.1 (19.4)

Diastolic blood pressure, mm Hg	79.4 (11.1)

HbA1c (NGSP), %	5.8 (0.8)

Total cholesterol, mg/dL	206.3 (35.1)

HDL cholesterol, mg/dL	62.6 (16.0)

Hypertension,bn	1,158 (46.9%)

Diabetes mellitus,cn	254 (10.3%)

Hypercholesterolemia,dn	1,030 (41.8%)

Low HDL cholesterol,en	181 (7.3%)

Age, years

Sex, women, n

Regular exercise,an

Smoking

Alcohol consumption, g/week

Body mass index, kg/m2

Systolic blood pressure, mm Hg

Diastolic blood pressure, mm Hg

HbA1c (NGSP), %

Total cholesterol, mg/dL

HDL cholesterol, mg/dL

Hypertension,bn

Diabetes mellitus,cn

Hypercholesterolemia,dn

Low HDL cholesterol,en

	All participants(N = 2,467)

Age, years	58.3 (15.7)

Sex, women, n	1,438 (58.3%)

Regular exercise,an	831 (33.8%)

Current smoker, n	381 (15.5%)

Ex-smoker, n	460 (18.7%)

Alcohol consumption, g/week	72.1 (133.7)

Body mass index, kg/m2	23.1 (3.4)

Systolic blood pressure, mm Hg	132.1 (19.4)

Diastolic blood pressure, mm Hg	79.4 (11.1)

HbA1c (NGSP), %	5.8 (0.8)

Total cholesterol, mg/dL	206.3 (35.1)

HDL cholesterol, mg/dL	62.6 (16.0)

Hypertension,bn	1,158 (46.9%)

Diabetes mellitus,cn	254 (10.3%)

Hypercholesterolemia,dn	1,030 (41.8%)

Low HDL cholesterol,en	181 (7.3%)


Characteristic	No. of participants (n = 15)

Age [median (range)]	47 (33–59)

Sex

Male	8

Female	7

Ethnicity

White British	13

Other	2

Profession

Surgeon	5

Clinical oncologist	3

Specialist nurse	4

Research nurse	1

Specialist radiographer	1

Speech and language therapist	1

Geographic area of sample, no.

North West England	4

North East England	2

South West England	1

London	4

South East England	3

Wales	1

Characteristic

Age [median (range)]

Sex

Male

Female

Ethnicity

White British

Other

Profession

Surgeon

Clinical oncologist

Specialist nurse

Research nurse

Specialist radiographer

Speech and language therapist

Geographic area of sample, no.

North West England

North East England

South West England

London

South East England

Wales


Data	Characteristics	Description

Classes of deprivation	Group 1: low deprivation	Census block with high median income, low proportion of households without a car, low proportion with non-owner-occupied primary residences

Group 2: moderate deprivation	Census block with median income average, medium proportion of households without a car, medium proportion with non-owner-occupied primary residences

Group 3: high deprivation	Census block with low median income, high proportion of households without a car, high proportion with non-owner-occupied primary residences

Classes of deprivation	Group 3: high deprivation	Census block with low median income, high proportion of households without a car, high proportion with non-owner-occupied primary residences


			95% Confidence Interval for odds

	P value	OR	Lower	Upper

Gender(female)			1.259	5.725

Jobless	<.001	1.870	1.412	2.478

Illegal Income	.001	1.617	1.217	2.150

Substance use of family members	.005	1.471	1.125	1.925

pleasure/enjoyment as cause of first injection	.001	1.583	1.209	2.074

First place of drug use (Roofless public places)	.003	1.558	1.157	2.097

First place of drug use (Roofed public places)	.019	1.621	1.084	2.424

Alone injection	<.001	.515	.388	.682

Groin injection	.013	1.642	1.111	2.427

Testis injection	.022	1.573	1.068	2.318

Nonfatal overdose	<.001	1.686	1.282	2.216

Arresting in past year	.022	1.385	1.049	1.829

			95% Confidence Interval for odds

	P value	O	L	Uppe

		R	ower	r

Gender(female)			1.259	5.725

Jobless	<.001	1.870	1.412	2.478

Illegal Income	.001	1.617	1.217	2.150

Substance use of family members	.005	1.471	1.125	1.925

pleasure/enjoyment as cause of first injection	.001	1.583	1.209	2.074

First place of drug use (Roofless public places)	.003	1.558	1.157	2.097

First place of drug use (Roofed public places)	.019	1.621	1.084	2.424

Alone injection	<.001	.515	.388	.682

Groin injection	.013	1.642	1.111	2.427

Testis injection	.022	1.573	1.068	2.318

Nonfatal overdose	<.001	1.686	1.282	2.216

Arresting in past year	.022	1.385	1.049	1.829


	Position at foot contact (deg)

	Flexion	Ext. tibial rot.	Varus

ICC	0.93	0.94	0.95

SEM (deg)	1.80	1.42	0.61

	Displacement during landing (deg)

	Flexion	Int. tibial rot.	Varus	Valgus

ICC	0.96	0.87	0.64	0.86

SEM (deg)	1.41	2.18	1.22	0.39

	Electromyographic data (%MVC)

	Rectus femoris	Hamstrings

ICC	0.79	0.62

SEM (%)	10.84	9.49

	Position at foot contact (deg)

SEM (deg)	1.80	1.42	0.61

	Displacement during landing (deg)

	Flexion	Int. tibial rot.	Varus	Valgus

ICC	0.96	0.87	0.64	0.86

SEM (deg)	1.41	2.18	1.22	0.39

	Electromyographic data (%MVC)

	Rectus femoris	Hamstrings

ICC	0.79	0.62

SEM (%)	10.84	9.49


	Metric	F	R2	p value*

HC (n = 29)vsRTT (n = 50)	Unweighted UniFrac	6.84	0.08	≤0.003

	Weighted UniFrac	15.6	0.16	≤0.003

	Bray-Curtis	6.94	0.08	≤0.003

HC (n = 29)vsRTT-C (n = 34)	Unweighted UniFrac	5.59	0.08	≤0.003

	Weighted UniFrac	12.1	0.16	≤0.003

	Bray-Curtis	5.39	0.08	≤0.003

HC (n = 29)vsRTT-NC (n = 14)	Unweighted UniFrac	5.27	0.11	≤0.003

	Weighted UniFrac	8.75	0.17	≤0.003

	Bray-Curtis	5.47	0.11	≤0.003

RTT-C (n = 34)vsRTT-NC (n = 14)	Unweighted UniFrac	1.31	0.02	0.180

	Weighted UniFrac	1.10	0.02	0.687

	Bray-Curtis	1.76	0.03	0.180


		CECA22*	CECA10	CECA6	CECA4

N° of items	22	10	6	4

Scoring distribution

Valid observations	132	133	134	134

Mean	44.9	44.6	38.8	53.4

SD	17.5	22.3	23.9	29.3

Percentile 50	43.7	40	37.5	53.1

% scoring 0	0	0	5	3 (2.2%)

% scoring 100	0	1	2	8 (5.9%)

Correlation item-global scoring	0.21–0.72	0.53–0.73	0.65–0.79	0.78–0.89

Reliability (Cronbach's alpha)	0.87	0.86	0.84	0.86

Results of Rasch analysis	Person separation	2.28	2.21	1.87	1.79

	Person reliability	0.84	0.83	0.78	0.76

		CECA22*	CECA10	CECA6	CECA4

scoring 100	0	1		(5.9%)

Correlation item-global scoring	0.21–0.72	0.53–0.73	0.65–0.79	0.78–0.89

Reliability (Cronbach's alpha)	0.87	0.86	0.84	0.86

Results of Rasch analysis	Person separation	2.28	2.21	1.87	1.79

	Person reliability	0.84	0.83	0.78	0.76


Insomnia (N = 17)	Controls (N = 15)	p-values


S. No	Lubricant	Speed (kmph)	Load (N)

1	Racer-4	40-60	10-50


Factors	Simple regression	Multiple regression

 	Unstandardizedcoefficient(B)	P value	Unstandardizedcoefficient(B)	Standardizedcoefficient(beta)	P value

Gly1057Asp polymorphism in IRS-2

 Asp/Asp(n = 41)	reference	 	reference	reference

 Gly/Gly(n = 69) + Gly/Asp(n = 80)	0.007	0.902	−0.023	−0.029	0.678

Age(year)	−0.002	0.245	−0.003	−0.107	0.147

Diabetes mellitus	0.194	<0.001	0.151	0.213	0.003

Hypertension	0.103	0.037	0.078	0.115	0.121

Male	0.019	0.697	−0.032	−0.048	0.574

Smoking	0.013	0.800	−0.012	−0.017	0.830

Total cholesterol(mmol/L)	0.033	0.197	0.040	0.114	0.103

Serum creatinine(μmol/L)	0.002	0.019	0.003	0.206	0.007

Body mass index(kg/m2)	0.023	<0.001	0.017	0.189	0.008

Factors	Simple regression	Multiple regression

	Unstandardizedcoefficient(B)	P value	Unstandardizedcoefficient(B)	Standardizedcoefficient(beta)	P value

Gly1057Asp polymorphism in IRS-2

Asp/Asp(n = 41)	reference		reference	reference

Gly/Gly(		0.90	−0.0	−	0.67

Factors	Simple regression	Multiple regression

	Unstandardizedcoefficient(B)	P value	Unstandardizedcoefficient(B)	Standardizedcoefficient(beta)	P value

n = 69) + Gly/Asp(n = 80)	0.007	2	23	0.029	8

Age(year)	−0.002	0.245	−0.003	−0.107	0.147

Diabetes mellitus	0.194	<0.001	0.151	0.213	0.003

Hypertension	0.103	0.037	0.078	0.115	0.121

Male	0.019	0.697	−0.032	−0.048	0.574

Smoking	0.013	0.800	−0.012	−0.017	0.830

Total cholesterol(mmol/L)	0.033	0.197	0.040	0.114	0.103

Serum creatinine(μmol/L)	0.002	0.019	0.003	0.206	0.007

Body mass index(kg/m2)	0.023	<0.001	0.017	0.189	0.008


Category	Part A	Part B	Part C	Total

Preferred Term	(N = 12)	(N = 10)	(N = 10)	(N = 32)

N (%)	N (%)	N (%)	N (%)

Subjects with Any Adverse Event	1 (8.3)	3 (30.0)	7 (70.0)	11 (34.4)

Subjects with Any Study Drug Related Adverse Event	0 (0.0)	0 (0.0)	1 (10.0)	1 (3.1)a

Subjects with Any Serious Adverse Event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Subjects with Any Study Drug Related Serious Adverse Event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Subjects with Any Adverse Event Leading to Discontinuation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Category	Part A	Part B	Part C	Total

Preferred Term	(N = 12)	(N = 10)	(N = 10)	(N = 32)

N (%)	N (%)	N (%)	N (%)

	1 (8.	3	7 (70.0)

Category	Part A	Part B	Part C	Total

Preferred Term	(N = 12)	(N = 10)	(N = 10)	(N = 32)

N (%)	N (%)	N (%)	N (%)

Subjects with Any Adverse Event	3)	 (30.0)		11 (34.4)

Subjects with Any Study Drug Related Adverse Event	0 (0.0)	0 (0.0)	1 (10.0)	1 (3.1)a

Subjects with Any Serious Adverse Event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Subjects with Any Study Drug Related Serious Adverse Event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Subjects with Any Adverse Event Leading to Discontinuation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)


	Phe-free milk	Phe-free amino acid powder (A-1)	Low Phe peptide powder (MP-11)

I (μg)	25	0	150

Se (μg)	1	2	11

Vit A (IU)	1500	0	0

Vit B1 (mg)	0.36	0	0

Vit B2 (mg)	0.6	0	0

Vit B6 (mg)	0.4	0	0

Vit B12	1	0	0

Vit C (mg)	48	0	0

Vit D (IU)	300	0	0

Vit E (mg)	4.38	0	0

Ca pantothenate (mg)	2	0	0

Niacin (mg)	5	0	0

Folate (mg)	0.1	0	0

Choline (mg)	50	0	0

Biotin (μg)	0	0	0.6


	25 JIA patientswith secondary LOE	28 JIA patientswithout secondary LOE

median age (range)	14.4 (6.0-27.0) years	13.8 (7.6-21.5) years

Sex	21 female, 4 male	18 female, 10 male

median ADM dose (range)	25.8 (10.7-58.8) mg/m2 every other week	24.3 (6.6-37.1) mg/m2 every other week

median duration of anti-TNF therapy (range)	2.2 (0.2-6.0) years	1.3 (0.2-10.4) years

MTX comedication	12/25 (48.0%)	15/28 (53.6%)

median MTX dose (range)	10.0 (3.9-12.1) mg/m2 weekly	10.8 (7.7-13.4) mg/m2 weekly


ETIOLOGY	NO. OF PATIENTS	PERCENTAGE

ONCOLOGICAL RES.	75	42.1%

TMJ ANKYLOSIS	35	19.6%

POST-TRAUMATIC	44	24.7%

OSTEOMYELITIS OF MANDIBLE	24	13.5%

TOTAL	178	100 %


 	Control	Intervention	Comparison	Treatment effect	P value

Maternal	n = 75	n = 79	 	(95% CI)

GDM	24 (32%)	22 (28%)	Risk difference	−4% (−19 to 13)	0.574

 	 	 	Risk ratio	0.87 (0.54 to 1.41)

Neonatal	n = 84	n = 86

LGA	7 (8%)	7 (8%)	Risk difference	0% (−8 to 8)	0.982

 	 	 	Risk ratio	0.99 (0.36 to 2.7)

>4 Kg	16 (19%)	13 (15%)	Risk difference	−4% (−15 to 8)	0.518


Green alga/land plant	Size (bp)	IR size (bp)	Genes (no.) a	Introns (no.) b	GenBank accession no.

Charophyceae

Chara vulgaris	184,933	10,919	127	2/16	GenBank:NC_008097

Chaetosphaeridium globosum	131,183	12,431	125	1/17	GenBank:NC_004115

Chlorokybus atmophyticus	152,254	7,640	138	1/0	GenBank:DQ422812

Mesostigma viride	118,360	6,057	137	0	GenBank:NC_002186

Staurastrum punctulatum	157,089	-	121	1/7	GenBank:NC_008116

Zygnema circumcarinatum	165,372	-	125	1/12	GenBank:NC_008117

Land Plants

Acorus calamus	153,821	25,697	110	1/20	GenBank:NC_007407

Amborella trichopoda	162,686	26,651	111	1/20	GenBank:NC_005086

Anthoceros formosae	161,162	15,744	120	2/20	GenBank:NC_004543

Arabidopsis thaliana	154,478	26,264	110	1/20	GenBank:NC_000932

Atropa belladonna	156,687	17,031	111	1/20	GenBank:NC_004561

Calycanthus floridus	153,337	23,296	111	1/20	GenBank:NC_004993

Cucumis sativus	155,293	24,753	111	1/20	GenBank:NC_007144

Eucalyptus globulus	160,286	26393	109	1/20	GenBank:NC_008115

Huperzia lucidula	154,373	15,314	119	1/20	GenBank:NC_006861

Lactuca sativa	152,765	25,033	111	1/20	GenBank:NC_007578

Lotus japonicus	150,519	25,156	109	1/20	GenBank:NC_002694

Marchantia polymorpha	121,024	10,058	120	1/19	GenBank:NC_001319

Nicotiana tabacum	155,939	25,341	110	1/20	GenBank:NC_001879

Nymphaea alba	159,930	25,177	111	1/20	GenBank:NC_006050

Oenothera elata	163,935	27,807	109	1/18	GenBank:NC_002693

Oryza sativa	134,525	20,799	108	1/17	GenBank:NC_001320

Panax ginseng	156,318	26,071	111	1/20	GenBank:NC_006290

Phalaenopsis aphrodite	148,964	23,787	99	1/18	GenBank:NC_007499

Physcomitrella patens	122,890	9,589	116	1/20	GenBank:NC_005087

Pinus thunbergii	119,707	-	106	1/15	GenBank:NC_001631

Saccharum officinarum	141,182	22795	108	1/17	GenBank:NC_006084

Spinacia oleracea	150,725	25,073	110	1/19	GenBank:NC_002202

Triticum aestivum	134,545	20,703	108	1/17	GenBank:NC_002762

Zea mays	140,384	22,748	108	1/17	GenBank:NC_001666

Prasinophyceae

Nephroselmis olivacea	200,799	46,137	128	0	GenBank:NC_000927

Trebouxiophyceae

Chlorella vulgaris	150,613	-	112	3/0	GenBank:NC_001865

Ulvophyceae

Oltmannsiellopsis viridis	151,933	18,510	104	5/0	GenBank:NC_008099

Pseudendoclonium akinetum	195,867	6,039	105	27/0	GenBank:NC_008114

Chlorophyceae

Chlamydomonas reinhardtii	203,827	22,211	94	5/2	GenBank:NC_005353

Scenedesmus obliquus	161,452	12,022	96	7/2	GenBank:NC_008101

Stigeoclonium helveticum	223,902	-	97	16/5	GenBank:DQ630521

Green alga/land plant

Charophyceae

Chara vulgaris

Chaetosphaeridium globosum

Chlorokybus atmophyticus

Mesostigma viride

Staurastrum punctulatum

Zygnema circumcarinatum

Land Plants

Acorus calamus

Amborella trichopoda

Anthoceros formosae

Arabidopsis thaliana

Atropa belladonna

Calycanthus floridus

Cucumis sativus

Eucalyptus globulus

Huperzia lucidula

Lactuca sativa

Lotus japonicus

Marchantia polymorpha

Nicotiana tabacum

Nymphaea alba

Oenothera elata

Oryza sativa

Panax ginseng

Phalaenopsis aphrodite

Physcomitrella patens

Pinus thunbergii

Saccharum officinarum

Spinacia oleracea

Triticum aestivum

Zea mays

Prasinophyceae

Nephroselmis olivacea

Trebouxiophyceae

Chlorella vulgaris

Ulvophyceae

Oltmannsiellopsis viridis

Pseudendoclonium akinetum

Chlorophyceae

Chlamydomonas reinhardtii

Scenedesmus obliquus

Stigeoclonium helveticum


	N-starved cells	P-starved cells

Total sequences collected	2,259,219	1,501,972

Total signatures	44,779	27,722

Reliable, significant signatures	27,217	20,161

Signatures unique to library	10,756	3,700

	N-starved cells	P-starved cells

Total signatures	44,779	27,722

Reliable, significant signatures	27,217	20,161

Signatures unique to library	10,756	3,700


	All patients (n = 129)

Age at diagnosis	59 (30-84)

Sex

Male	96 (74.4%)

Female	33 (25.6%)

Histology

Adeno, WD	7 (5.4%)

Adeno, MD	76 (58.9%)

Adeno, PD	33 (25.6%)

SRC carcinoma	13 (10.1%)

Previous surgery

Yes	42 (32.6%)

No	87 (67.4%)

Location of tumor

Proximal	31 (24.0%)

Distal	98 (76.0%)

Peritoneal metastasis

Yes	45 (34.9%)

No	84 (65.1%)

Liver metastasis

Yes	53 (41.1%)

No	76 (58.9%)

Bone metastasis

Yes	15 (11.6%)

No	104 (80.6%)

N/A	10 (7.8%)

Lung metastasis

Yes	16 (12.4%)

No	113 (87.6%)

Performance status

ECOG 0	72 (55.8%)

ECOG 1	42 (32.6%)

ECOG ≥2	15 (11.7%)

Regimen

Herceptin-FP	17 (13.2%)

Herceptin-XP	112 (86.8%)

HER2 IHC

2+	31 (24.0%)

3+	98 (76.0%)

HER2 amplification index	7.0 ± 5.9

PTEN expression

Loss	11 (16.4%)

Intact	56 (83.6%)

PIK3R1 genotype

Variant	16 (23.2%)

Wildtype	53 (76.8%)


	CKD (n= 6)	CKD + pravastatin (n= 5)

Focal glomerulosclerosis (%)

 Normal	32.9 ± 7.6	23.4 ± 13.1

 Partial	48.1 ± 10.6	62.7 ± 10.4

 Total	19.0 ± 6.7	14.0 ± 15.8

Tubulo-interstitial damage

 Fibrosis	0.78 ± 0.31	0.85 ± 0.14

 Inflammation	1.72 ± 0.54	1.66 ± 0.22

 Atrophy	1.09 ± 0.65	0.56 ± 0.09

Focal glomerulosclerosis (%)

Normal

Partial

Total

Tubulo-interstitial damage

Fibrosis

Inflammation

Atrophy


Dependent variables:	Complaints of generalised anxiety

	MEN	WOMEN

	B	B

Intercept	-0.027 ***	-0.004

Contextual effects

Unemployment rate	0.032	0.075

Median area income (in euros)	0.245	1.214

Density	-0.081	0.032

Individual effects

Social support	-0.018 ***	-0.028 ***

Current employment situation (ref.: paid labour)

Retired	0.003	0.003

Disabled	0.091 ***	0.101 ***

Unemployed	0.022 ***	0.022 ***

Househusband/wife	-0.028	-0.011 *

Student and others	0.032 **	0.102

Educational level (ref.: tertiary education)

No diploma or primary education	0.008 *	0.038 ***

Lower secondary	0.009 *	0.017 ***

Higher secondary	-0.001	0.010 ***

Equivalent income of the household (ref.: > 2.500 €)

< 750 €	0.018 **	0.017 *

750 - 1.000 €	0.009	0.013 *

1.000 - 1.500 €	0.002	0.005

1.500 - 2.500 €	-0.002	-0.002

Missing income	-0.008	-0.011 *

Age	-0.002	-0.002

Household type (ref.: couple with child(ren))

Single	-0.001	-0.001

Single with child(ren)	-0.010	0.008

Couple	0.006	0.009 *

Complex household	0.004	0.003

Dependent variables:	Complaints of generalised anxiety

	MEN	WOMEN

	B	B

Intercept	-0.027 ***	-0.004

Contextual effects

Unemployment	0.032

 rate		0.075

Median area income (in euros)	0.245	1.214

Density	-0.081	0.032

Individual effects

Social support	-0.018 ***	-0.028 ***

Current employment situation (ref.: paid labour)

Retired	0.003	0.003

Disabled	0.091 ***	0.101 ***

Unemployed	0.022 ***	0.022 ***

Househusband/wife	-0.028	-0.011 *

Student and others	0.032 **	0.102

Educational level (ref.: tertiary education)

No diploma or primary education	0.008 *	0.038 ***

Lower secondary	0.009 *	0.017 ***

Higher secondary	-0.001	0.010 ***

Equivalent income of the household (ref.: > 2.500 €)

< 750 €	0.018 **	0.017 *

750 - 1.000 €	0.009	0.013 *

1.000 - 1.500 €	0.002	0.005

1.500 - 2.500 €	-0.002	-0.002

Missing income	-0.008	-0.011 *

Age	-0.002	-0.002

Household type (ref.: couple with child(ren))

Single	-0.001	-0.001

Single with child(ren)	-0.010	0.008

Couple	0.006	0.009 *

Complex household	0.004	0.003